

Philip Scheltens

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2896216/philip-scheltens-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

1,347
papers

89,592
citations

131
h-index

272
g-index

1,593
ext. papers

107,631
ext. citations

5.9
avg. IF

7.88
L-index

#	Paper	IF	Citations
1347	The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimeris and Dementia</i> , 2011 , 7, 263-9	1.2	8211
1346	Consistent resting-state networks across healthy subjects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 13848-53	11.5	3210
1345	NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimeris and Dementia</i> , 2018 , 14, 535-562	1.2	3155
1344	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. <i>Lancet Neurology, The</i> , 2007 , 6, 734-46	24.1	3067
1343	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology, The</i> , 2014 , 13, 614-29	24.1	1985
1342	Alzheimer's disease. <i>Lancet, The</i> , 2016 , 388, 505-17	40	1720
1341	Mild cognitive impairment. <i>Lancet, The</i> , 2006 , 367, 1262-70	40	1703
1340	Risk of dementia in diabetes mellitus: a systematic review. <i>Lancet Neurology, The</i> , 2006 , 5, 64-74	24.1	1424
1339	A new rating scale for age-related white matter changes applicable to MRI and CT. <i>Stroke</i> , 2001 , 32, 1318-22	12.2	1270
1338	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimeris and Dementia</i> , 2014 , 10, 844-52	1.2	1219
1337	The clinical use of structural MRI in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2010 , 6, 67-77	15	1131
1336	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology, The</i> , 2016 , 15, 455-532	24.1	921
1335	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1924-38	27.4	842
1334	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimeris and Dementia</i> , 2016 , 12, 292-323	1.2	832
1333	CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 385-93	27.4	758
1332	A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. <i>Journal of the Neurological Sciences</i> , 1993 , 114, 7-12	3.2	744
1331	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016 , 87, 539-47	6.5	710

1330	Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. <i>Brain</i> , 2009 , 132, 213-24	11.2	689
1329	Treatment of Alzheimer's disease: current status and new perspectives. <i>Lancet Neurology, The</i> , 2003 , 2, 539-47	24.1	590
1328	Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. <i>Human Brain Mapping</i> , 2005 , 26, 231-9	5.9	589
1327	White matter hyperintensities, cognitive impairment and dementia: an update. <i>Nature Reviews Neurology</i> , 2015 , 11, 157-65	15	518
1326	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. <i>Lancet Neurology, The</i> , 2009 , 8, 619-27	24.1	473
1325	Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. <i>NeuroImage</i> , 2004 , 23, 708-16	7.9	449
1324	Loss of 'small-world' networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. <i>PLoS ONE</i> , 2010 , 5, e13788	3.7	434
1323	Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 126-35	5.5	430
1322	Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 714-8	5.5	422
1321	Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1939-49	27.4	379
1320	Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. <i>Alzheimer Disease and Associated Disorders</i> , 2014 , 28, 206-18	2.5	373
1319	Cognitive impairment in heart failure: a systematic review of the literature. <i>European Journal of Heart Failure</i> , 2007 , 9, 440-9	12.3	368
1318	Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. <i>Alzheimeris and Dementia</i> , 2011 , 7, 367-85	1.2	364
1317	A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. <i>NeuroImage</i> , 2003 , 18, 895-907	7.9	347
1316	Impact of age-related cerebral white matter changes on the transition to disability -- the LADIS study: rationale, design and methodology. <i>Neuroepidemiology</i> , 2005 , 24, 51-62	5.4	345
1315	Advances in the early detection of Alzheimer's disease. <i>Nature Medicine</i> , 2004 , 10 Suppl, S34-41	50.5	332
1314	The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. <i>Ageing Research Reviews</i> , 2016 , 25, 13-23	12	330
1313	Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. <i>Brain</i> , 2003 , 126, 2016-22	11.2	330

1312	EFNS guidelines for the diagnosis and management of Alzheimer's disease. <i>European Journal of Neurology</i> , 2010 , 17, 1236-48	6	329
1311	Deficits of memory, executive functioning and attention following infarction in the thalamus; a study of 22 cases with localised lesions. <i>Neuropsychologia</i> , 2003 , 41, 1330-44	3.2	319
1310	Circadian rest-activity rhythm disturbances in Alzheimer's disease. <i>Biological Psychiatry</i> , 1996 , 40, 259-70.9		309
1309	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology, The</i> , 2017 , 16, 661-676	24.1	308
1308	Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. <i>Stroke</i> , 2008 , 39, 1414-20	6.7	299
1307	Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. <i>Journal of Neurology</i> , 1995 , 242, 557-60	5.5	285
1306	Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. <i>European Neurology</i> , 1996 , 36, 268-72	2.1	284
1305	Early-versus late-onset Alzheimer's disease: more than age alone. <i>Journal of Alzheimer's Disease</i> , 2010 , 19, 1401-8	4.3	282
1304	Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways. <i>Hippocampus</i> , 2000 , 10, 398-410	3.5	282
1303	Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. <i>Neurobiology of Aging</i> , 2013 , 34, 2023-36	5.6	279
1302	Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. <i>Lancet Neurology, The</i> , 2002 , 1, 13-21	24.1	279
1301	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. <i>Neurobiology of Aging</i> , 2012 , 33, 1203-14	5.6	278
1300	Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. <i>BMJ, The</i> , 2009 , 339, b2477	5.9	277
1299	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. <i>Brain</i> , 2015 , 138, 2732-49	11.2	275
1298	Brain imaging in patients with diabetes: a systematic review. <i>Diabetes Care</i> , 2006 , 29, 2539-48	14.6	275
1297	Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. <i>Stroke</i> , 2005 , 36, 2116-20	6.7	266
1296	Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. <i>Neurology</i> , 2004 , 63, 94-100	6.5	265
1295	Consensus classification of posterior cortical atrophy. <i>Alzheimer's and Dementia</i> , 2017 , 13, 870-884	1.2	261

1294	Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. <i>Lancet Neurology, The</i> , 2007 , 6, 501-12	24.1	260
1293	Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. <i>BMC Neuroscience</i> , 2009 , 10, 101	3.2	258
1292	Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. <i>Journal of Neurology</i> , 1999 , 246, 477-85	5.5	257
1291	Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. <i>Clinical Chemistry</i> , 2010 , 56, 248-53	5.5	256
1290	Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2012 , 33, 2018-28	5.6	253
1289	Activity dependent degeneration explains hub vulnerability in Alzheimer's disease. <i>PLoS Computational Biology</i> , 2012 , 8, e1002582	5	253
1288	Magnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer's disease. <i>NeuroImage</i> , 2006 , 32, 1335-44	7.9	251
1287	Alzheimer's disease. <i>Lancet, The</i> , 2021 , 397, 1577-1590	40	245
1286	A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 95	9	243
1285	Optimizing patient care and research: the Amsterdam Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 313-27	4.3	243
1284	Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. <i>Stroke</i> , 2003 , 34, 441-5	6.7	240
1283	Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. <i>Stroke</i> , 2006 , 37, 836-40	6.7	236
1282	Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , 2018 , 136, 821-853	14.3	236
1281	Drug development in Alzheimer's disease: the path to 2025. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 39	9	234
1280	Visual assessment of posterior atrophy development of a MRI rating scale. <i>European Radiology</i> , 2011 , 21, 2618-25	8	223
1279	Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. <i>Archives of Neurology</i> , 2006 , 63, 538-43		222
1278	The clinical profile of right temporal lobe atrophy. <i>Brain</i> , 2009 , 132, 1287-98	11.2	220
1277	Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE e4 allele. <i>Lancet Neurology, The</i> , 2011 , 10, 280-8	24.1	218

1276	Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges. <i>Journal of Alzheimeris Disease</i> , 2016 , 49, 617-31	4.3	214
1275	Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. <i>Hypertension</i> , 2004 , 44, 29-34	8.5	213
1274	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015 , 138, 1327-38	11.2	211
1273	Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. <i>Neuroradiology</i> , 2007 , 49, 967-76	3.2	209
1272	White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. <i>European Neurology</i> , 1998 , 39, 80-9	2.1	208
1271	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , 2014 , 13, 686-99	24.1	207
1270	Heterogeneity in age-related white matter changes. <i>Acta Neuropathologica</i> , 2011 , 122, 171-85	14.3	206
1269	Blood-brain barrier P-glycoprotein function in Alzheimer's disease. <i>Brain</i> , 2012 , 135, 181-9	11.2	205
1268	The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. <i>Alzheimeris and Dementia</i> , 2014 , 10, 713-723.e2	1.2	204
1267	Altered temporal correlations in parietal alpha and prefrontal theta oscillations in early-stage Alzheimer disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 1614-9	11.5	204
1266	EEG synchronization in mild cognitive impairment and Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2003 , 108, 90-6	3.8	203
1265	Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. <i>Journal of Alzheimeris Disease</i> , 2012 , 31, 225-36	4.3	202
1264	Generalized synchronization of MEG recordings in Alzheimer's Disease: evidence for involvement of the gamma band. <i>Journal of Clinical Neurophysiology</i> , 2002 , 19, 562-74	2.2	202
1263	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. <i>Alzheimeris and Dementia</i> , 2015 , 11, 1180-90	1.2	201
1262	On the path to 2025: understanding the Alzheimer's disease continuum. <i>Alzheimeris Research and Therapy</i> , 2017 , 9, 60	9	197
1261	2001-2011: A Decade of the LADIS (Leukoaraiosis And DISability) Study: What Have We Learned about White Matter Changes and Small-Vessel Disease?. <i>Cerebrovascular Diseases</i> , 2011 , 32, 577-588	3.2	197
1260	Vascular cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 18003	51.1	195
1259	Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. <i>Brain</i> , 2008 , 131, 3286-98	11.2	195

1258	White matter tract integrity in aging and Alzheimer's disease. <i>Human Brain Mapping</i> , 2009 , 30, 1051-9	5.9	194
1257	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: the CADDementia challenge. <i>NeuroImage</i> , 2015 , 111, 562-79	7.9	193
1256	Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. <i>Alzheimeris and Dementia</i> , 2010 , 6, 1-10.e1	1.2	193
1255	EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. <i>European Journal of Neurology</i> , 2012 , 19, 1159-79	6	191
1254	EEG synchronization likelihood in mild cognitive impairment and Alzheimer's disease during a working memory task. <i>Clinical Neurophysiology</i> , 2004 , 115, 1332-9	4.3	191
1253	Disturbed fluctuations of resting state EEG synchronization in Alzheimer's disease. <i>Clinical Neurophysiology</i> , 2005 , 116, 708-15	4.3	186
1252	Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. <i>Lancet, The</i> , 2001 , 358, 455-60	4.0	183
1251	Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. <i>Stroke</i> , 2009 , 40, 3455-60	6.7	179
1250	Imaging markers for Alzheimer disease: which vs how. <i>Neurology</i> , 2013 , 81, 487-500	6.5	173
1249	fMRI of visual encoding: reproducibility of activation. <i>Human Brain Mapping</i> , 2000 , 9, 156-64	5.9	173
1248	Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. <i>Radiology</i> , 2013 , 267, 221-30	20.5	170
1247	Noradrenaline mediates amygdala activation in men and women during encoding of emotional material. <i>NeuroImage</i> , 2005 , 24, 898-909	7.9	164
1246	Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer's disease. <i>NeuroImage</i> , 2012 , 59, 3085-93	7.9	160
1245	Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. <i>Diabetes Care</i> , 2006 , 29, 2268-74	14.6	154
1244	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. <i>JAMA Neurology</i> , 2015 , 72, 1275-80	17.2	152
1243	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014 , 23, 6139-46	5.6	152
1242	Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. <i>Archives of Neurology</i> , 2007 , 64, 108-15		151
1241	Brain health: the importance of recognizing cognitive impairment: an IAGG consensus conference. <i>Journal of the American Medical Directors Association</i> , 2015 , 16, 731-9	5.9	149

1240	Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 18	9	148
1239	Qualitative assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in dementia and normal aging. <i>European Neurology</i> , 1997 , 37, 95-9	2.1	148
1238	Diabetic encephalopathy: A concept in need of a definition. <i>Diabetologia</i> , 2006 , 49, 1447-8	10.3	147
1237	Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 1464-70	8.9	145
1236	Within-subject reproducibility of visual activation patterns with functional magnetic resonance imaging using multislice echo planar imaging. <i>Magnetic Resonance Imaging</i> , 1998 , 16, 105-13	3.3	145
1235	Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. <i>Human Brain Mapping</i> , 2015 , 36, 4421-37	5.9	142
1234	A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Annals of Clinical Biochemistry</i> , 2009 , 46, 235-40	2.2	140
1233	Age, hypertension, and lacunar stroke are the major determinants of the severity of age-related white matter changes. The LADIS (Leukoaraiosis and Disability in the Elderly) Study. <i>Cerebrovascular Diseases</i> , 2006 , 21, 315-22	3.2	140
1232	Cerebrospinal fluid A β 2 is the best predictor of clinical progression in patients with subjective complaints. <i>Alzheimer's and Dementia</i> , 2013 , 9, 481-7	1.2	139
1231	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011 , 7, 474-485.e4	1.2	139
1230	Longitudinal cognitive decline in subcortical ischemic vascular disease--the LADIS Study. <i>Cerebrovascular Diseases</i> , 2009 , 27, 384-91	3.2	139
1229	Profile of cognitive impairment in chronic heart failure. <i>Journal of the American Geriatrics Society</i> , 2007 , 55, 1764-70	5.6	139
1228	CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2007 , 28, 1070-4	5.6	139
1227	The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. <i>Alzheimer's and Dementia</i> , 2015 , 11, 111-25	1.2	137
1226	Impact of molecular imaging on the diagnostic process in a memory clinic. <i>Alzheimer's and Dementia</i> , 2013 , 9, 414-21	1.2	137
1225	Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. <i>Diabetologia</i> , 2006 , 49, 2474-80	10.3	137
1224	Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. <i>Clinical Chemistry</i> , 2005 , 51, 189-95	5.5	137
1223	Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. <i>Annals of Neurology</i> , 2018 , 84, 648-658	9.4	137

1222	MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. <i>Brain</i> , 2016 , 139, 1211-25	11.2	135
1221	Endogenous cortisol level interacts with noradrenergic activation in the human amygdala. <i>Neurobiology of Learning and Memory</i> , 2007 , 87, 57-66	3.1	134
1220	Amnesic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. <i>American Journal of Neuroradiology</i> , 2008 , 29, 944-9	4.4	133
1219	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. <i>Alzheimeris and Dementia</i> , 2019 , 15, 888-898	1.2	131
1218	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. <i>Neurology</i> , 2013 , 80, 1048-56	6.5	131
1217	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimeris and Dementia</i> , 2016 , 12, 154-163	1.2	129
1216	Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. <i>Neuroscience Letters</i> , 2000 , 285, 231-3	3.3	129
1215	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 111-126	5.2	128
1214	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimeris and Dementia</i> , 2019 , 15, 465-476	1.2	127
1213	Microglial activation in Alzheimer's disease: an (R)-[¹¹ C]PK11195 positron emission tomography study. <i>Neurobiology of Aging</i> , 2013 , 34, 128-36	5.6	126
1212	Magnetoencephalographic analysis of cortical activity in Alzheimer's disease: a pilot study. <i>Clinical Neurophysiology</i> , 2000 , 111, 604-12	4.3	124
1211	Visual association encoding activates the medial temporal lobe: a functional magnetic resonance imaging study. <i>Hippocampus</i> , 1997 , 7, 594-601	3.5	123
1210	Amsterdam Dementia Cohort: Performing Research to Optimize Care. <i>Journal of Alzheimeris Disease</i> , 2018 , 62, 1091-1111	4.3	122
1209	Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. <i>Stroke</i> , 2003 , 34, 1907-12	6.7	122
1208	Early onset Alzheimer's disease is associated with a distinct neuropsychological profile. <i>Journal of Alzheimeris Disease</i> , 2012 , 30, 101-8	4.3	121
1207	Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013 , 34, 2014-22	5.6	120
1206	Pathophysiologic mechanisms in the development of age-related white matter changes of the brain. <i>Dementia and Geriatric Cognitive Disorders</i> , 1998 , 9 Suppl 1, 2-5	2.6	119
1205	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , 2017 , 16, 965-975	24.1	118

1204	Cognitive impairment and MRI correlates in the elderly patients with type 2 diabetes mellitus. <i>Age and Ageing</i> , 2007 , 36, 164-70	3	117
1203	Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 990-1000	8.8	116
1202	Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2003 , 110, 949-55	4.3	116
1201	Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1570-6	8.9	115
1200	Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. <i>JAMA Neurology</i> , 2014 , 71, 855-62	17.2	113
1199	Progression of mild cognitive impairment to dementia: contribution of cerebrovascular disease compared with medial temporal lobe atrophy. <i>Stroke</i> , 2009 , 40, 1269-74	6.7	112
1198	Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease. <i>NeuroImage</i> , 2005 , 26, 1078-85	7.9	112
1197	Regional distribution of white matter hyperintensities in vascular dementia, Alzheimer's disease and healthy aging. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004 , 18, 180-8	2.6	112
1196	Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 1325-30	5.5	111
1195	Microglial activation in healthy aging. <i>Neurobiology of Aging</i> , 2012 , 33, 1067-72	5.6	110
1194	Incidence of depression and anxiety in the spouses of patients with dementia: a naturalistic cohort study of recorded morbidity with a 6-year follow-up. <i>American Journal of Geriatric Psychiatry</i> , 2010 , 18, 146-53	6.5	110
1193	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. <i>Neurology</i> , 2012 , 79, 1809-16	6.5	110
1192	World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. <i>Alzheimeris and Dementia</i> , 2020 , 16, 1078-1094	1.2	109
1191	Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 191-7	8.9	108
1190	Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011 , 49, 353-66	5.9	108
1189	Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 524-31	5	108
1188	Model-free group analysis shows altered BOLD FMRI networks in dementia. <i>Human Brain Mapping</i> , 2009 , 30, 256-66	5.9	107
1187	Inflammatory markers in AD and MCI patients with different biomarker profiles. <i>Neurobiology of Aging</i> , 2009 , 30, 1885-9	5.6	107

1186	Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. <i>Radiology</i> , 2008 , 248, 590-8	20.5	107
1185	Brain magnetic resonance imaging abnormalities in patients with heart failure. <i>European Journal of Heart Failure</i> , 2007 , 9, 1003-9	12.3	107
1184	Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. <i>Current Medical Research and Opinion</i> , 2008 , 24, 2561-74	2.5	106
1183	Preclinical AD predicts decline in memory and executive functions in subjective complaints. <i>Neurology</i> , 2013 , 81, 1409-16	6.5	104
1182	Imaging of white matter lesions. <i>Cerebrovascular Diseases</i> , 2002 , 13 Suppl 2, 21-30	3.2	104
1181	Clinical relevance of improved microbleed detection by susceptibility-weighted magnetic resonance imaging. <i>Stroke</i> , 2011 , 42, 1894-900	6.7	103
1180	Brain lesions on MRI in elderly patients with type 2 diabetes mellitus. <i>European Neurology</i> , 2007 , 57, 70-4.1	4.1	103
1179	Glucocorticoids Decrease Hippocampal and Prefrontal Activation during Declarative Memory Retrieval in Young Men. <i>Brain Imaging and Behavior</i> , 2007 , 1, 31-41	4.1	101
1178	Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. <i>Journal of Neurology</i> , 2006 , 253, 1189-96	5.5	101
1177	Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. <i>Annals of Neurology</i> , 2003 , 53, 547-8	9.4	101
1176	Biomarkers for Alzheimer's disease therapeutic trials. <i>Progress in Neurobiology</i> , 2011 , 95, 579-93	10.9	100
1175	MRI biomarkers of vascular damage and atrophy predicting mortality in a memory clinic population. <i>Stroke</i> , 2009 , 40, 492-8	6.7	99
1174	Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. <i>Brain</i> , 2013 , 136, 2707-16	11.2	98
1173	Prediction of Alzheimer disease in subjects with amnesic and nonamnesic MCI. <i>Neurology</i> , 2013 , 80, 1124-32	6.5	97
1172	Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. <i>Radiology</i> , 2009 , 253, 174-83	20.5	97
1171	CSF biomarker levels in early and late onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009 , 30, 1895-906	9.6	97
1170	Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients. <i>Journal of the Neurological Sciences</i> , 1994 , 121, 46-9	3.2	97
1169	Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. <i>Neurology</i> , 2015 , 84, 508-15	6.5	96

1168	Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation—a pharmacological fMRI study. <i>Brain</i> , 2006 , 129, 141-57	11.2	96
1167	White matter lesions and hippocampal atrophy in Alzheimer's disease. <i>Neurology</i> , 2004 , 62, 310-2	6.5	96
1166	Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage. <i>Frontiers in Aging Neuroscience</i> , 2013 , 5, 58	5.3	95
1165	Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study. <i>Psychological Medicine</i> , 2010 , 40, 603-10	6.9	95
1164	Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?. <i>Annals of Neurology</i> , 2005 , 58, 139-42	9.4	95
1163	Differential regional atrophy of the cingulate gyrus in Alzheimer disease: a volumetric MRI study. <i>Cerebral Cortex</i> , 2006 , 16, 1701-8	5.1	95
1162	Amyloid-PET and F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , 2020 , 19, 951-962	24.1	95
1161	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95	14.5	94
1160	The "rights" of precision drug development for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 76	9	93
1159	Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 801-7	4.3	93
1158	P-glycoprotein function at the blood-brain barrier: effects of age and gender. <i>Molecular Imaging and Biology</i> , 2012 , 14, 771-6	3.8	92
1157	Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. <i>NeuroImage</i> , 2004 , 23, 1450-9	7.9	92
1156	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. <i>Brain</i> , 2012 , 135, 2115-25	11.2	91
1155	The two-year incidence of depression and anxiety disorders in spousal caregivers of persons with dementia: who is at the greatest risk?. <i>American Journal of Geriatric Psychiatry</i> , 2015 , 23, 293-303	6.5	89
1154	Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume. <i>Diabetologia</i> , 2007 , 50, 1763-9	10.3	88
1153	The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia. <i>Stroke</i> , 2007 , 38, 3182-5	6.7	88
1152	Hippocampal shape analysis in Alzheimer's disease: a population-based study. <i>NeuroImage</i> , 2007 , 36, 8-18	7.9	88
1151	Early diagnosis of dementia: neuroimaging. <i>Journal of Neurology</i> , 1999 , 246, 16-20	5.5	88

1150	CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2008 , 29, 669-75	5.6	87
1149	The functional basis of ocular dominance: functional MRI (fMRI) findings. <i>Neuroscience Letters</i> , 1996 , 221, 1-4	3.3	87
1148	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015 , 138, 2701-15.2	5.2	86
1147	Relationship between periventricular and deep white matter lesions and depressive symptoms in older people. The LADIS Study. <i>International Journal of Geriatric Psychiatry</i> , 2006 , 21, 983-9	3.9	86
1146	Declining functional connectivity and changing hub locations in Alzheimer's disease: an EEG study. <i>BMC Neurology</i> , 2015 , 15, 145	3.1	85
1145	Assessing mental flexibility: neuroanatomical and neuropsychological correlates of the Trail Making Test in elderly people. <i>Clinical Neuropsychologist</i> , 2010 , 24, 203-19	4.4	85
1144	The diagnostic value of electroencephalography in mild senile Alzheimer's disease. <i>Clinical Neurophysiology</i> , 1999 , 110, 825-32	4.3	85
1143	Brain network alterations in Alzheimer's disease measured by eigenvector centrality in fMRI are related to cognition and CSF biomarkers. <i>Human Brain Mapping</i> , 2014 , 35, 2383-93	5.9	84
1142	Limitations of clinical criteria for the diagnosis of vascular dementia in clinical trials. Is a focus on subcortical vascular dementia a solution?. <i>Annals of the New York Academy of Sciences</i> , 2000 , 903, 262-72	6.5	84
1141	Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. <i>World Journal of Biological Psychiatry</i> , 2005 , 6, 69-84	3.8	83
1140	Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 547-51	5.5	82
1139	Multicenter assessment of reliability of cranial MRI. <i>Neurobiology of Aging</i> , 2006 , 27, 1051-9	5.6	82
1138	The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. <i>PLoS ONE</i> , 2014 , 9, e86558	3.7	82
1137	EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. <i>European Journal of Neurology</i> , 2015 , 22, 889-98	6	81
1136	Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset. <i>Psychological Medicine</i> , 2009 , 39, 1907-11	6.9	81
1135	Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes. <i>European Journal of Pharmacology</i> , 2008 , 585, 88-96	5.3	81
1134	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 59	9	80
1133	Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. <i>Neurology</i> , 2013 , 80, 359-65	6.5	80

1132	Single-subject grey matter graphs in Alzheimer's disease. <i>PLoS ONE</i> , 2013 , 8, e58921	3.7	80
1131	CSF β -synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2010 , 22, 87-95	4.3	80
1130	Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. <i>Diabetic Medicine</i> , 2007 , 24, 166-71	3.5	80
1129	Diagnostic impact of [18 F]flutemetamol PET in early-onset dementia. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 2	9	79
1128	Can nutrients prevent or delay onset of Alzheimer's disease?. <i>Journal of Alzheimer's Disease</i> , 2010 , 20, 765-75	4.3	79
1127	Simplified parametric methods for [11 C]PIB studies. <i>NeuroImage</i> , 2008 , 42, 76-86	7.9	79
1126	Physical activity prevents progression for cognitive impairment and vascular dementia: results from the LADIS (Leukoaraiosis and Disability) study. <i>Stroke</i> , 2012 , 43, 3331-5	6.7	78
1125	Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. <i>Neurobiology of Aging</i> , 2010 , 31, 758-64	5.6	77
1124	Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. <i>Alzheimer's and Dementia</i> , 2018 , 14, 707-722	1.2	76
1123	Corpus callosum atrophy is associated with mental slowing and executive deficits in subjects with age-related white matter hyperintensities: the LADIS Study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 491-6	5.5	76
1122	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid- β -42 Analysis Results. <i>Clinical Chemistry</i> , 2018 , 64, 576-585	5.5	76
1121	Periventricular white matter hyperintensities increase the likelihood of progression from amnesic mild cognitive impairment to dementia. <i>Journal of Neurology</i> , 2008 , 255, 1302-8	5.5	75
1120	Identifying confounds to increase specificity during a "no task condition". Evidence for hippocampal connectivity using fMRI. <i>NeuroImage</i> , 2003 , 20, 1236-45	7.9	75
1119	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019 , 15, 776-787	1.2	74
1118	Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. <i>European Radiology</i> , 2009 , 19, 2826-33	8	74
1117	Global dynamical analysis of the EEG in Alzheimer's disease: frequency-specific changes of functional interactions. <i>Clinical Neurophysiology</i> , 2008 , 119, 837-41	4.3	74
1116	Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. <i>Archives of Neurology</i> , 1999 , 56, 961-5		74
1115	Prevalence of amyloid- β pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018 , 84, 729-740	9.4	74

1114	Disruption of functional brain networks in Alzheimer's disease: what can we learn from graph spectral analysis of resting-state magnetoencephalography?. <i>Brain Connectivity</i> , 2012 , 2, 45-55	2.7	73
1113	White matter lesion progression in LADIS: frequency, clinical effects, and sample size calculations. <i>Stroke</i> , 2012 , 43, 2643-7	6.7	73
1112	MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2000 , 15, 911-6	3.9	73
1111	Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. <i>Brain</i> , 2017 , 140, 1466-1485	11.2	72
1110	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. <i>Neurobiology of Aging</i> , 2012 , 33, 2272-81	5.6	72
1109	Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. <i>Psychological Medicine</i> , 2013 , 43, 911-20	6.9	72
1108	An algorithmic approach to structural imaging in dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 692-8	5.5	71
1107	Neuroimaging and correlates of cognitive function among patients with heart failure. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 24, 418-23	2.6	71
1106	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. <i>JAMA Neurology</i> , 2018 , 75, 1062-1070	17.3	70
1105	Diffusion-weighted imaging and cognition in the leukoaraiosis and disability in the elderly study. <i>Stroke</i> , 2010 , 41, e402-8	6.7	70
1104	MRI-defined subcortical ischemic vascular disease: baseline clinical and neuropsychological findings. The LADIS Study. <i>Cerebrovascular Diseases</i> , 2009 , 27, 336-44	3.2	70
1103	Cerebral perfusion in the prodementia stages of Alzheimer's disease. <i>European Radiology</i> , 2016 , 26, 506-84	6.8	69
1102	Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2013 , 34, 2003-13	5.6	69
1101	Regional white matter integrity differentiates between vascular dementia and Alzheimer disease. <i>Stroke</i> , 2009 , 40, 773-9	6.7	69
1100	Differences in nutritional status between very mild Alzheimer's disease patients and healthy controls. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 261-71	4.3	68
1099	Urinary complaints in nondisabled elderly people with age-related white matter changes: the Leukoaraiosis And DISability (LADIS) Study. <i>Journal of the American Geriatrics Society</i> , 2008 , 56, 1638-43	5.6	68
1098	Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. <i>Neurology</i> , 2018 , 90, e149-e156	6.5	68
1097	Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas. <i>Acta Neuropathologica Communications</i> , 2018 , 6, 147	7.3	67

1096	BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. <i>Journal of Alzheimer's Disease</i> , 2010 , 20, 253-60	4.3	66
1095	Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. <i>Archives of General Psychiatry</i> , 2009 , 66, 1263-70		66
1094	Early-onset dementia is associated with higher mortality. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 26, 147-52	2.6	66
1093	Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 10-22	6	65
1092	Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?. <i>European Radiology</i> , 2015 , 25, 3050-9	8	65
1091	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. <i>European Radiology</i> , 2017 , 27, 1169-1175	8	65
1090	On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. <i>Stroke</i> , 2008 , 39, 3083-5	6.7	65
1089	Receiving a diagnosis of dementia: The experience over time. <i>Dementia</i> , 2006 , 5, 397-410	3	65
1088	Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 531-540	1.2	64
1087	A new informant-based questionnaire for instrumental activities of daily living in dementia. <i>Alzheimer's and Dementia</i> , 2012 , 8, 536-43	1.2	64
1086	Reliability and sensitivity of visual scales versus volumetry for evaluating white matter hyperintensity progression. <i>Cerebrovascular Diseases</i> , 2008 , 25, 247-53	3.2	64
1085	Development of screening guidelines and clinical criteria for prodementia Alzheimer's disease. The DESCRIPA Study. <i>Neuroepidemiology</i> , 2008 , 30, 254-65	5.4	64
1084	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016 , 12, 862-71	1.2	64
1083	Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 425-32	5.5	63
1082	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 5	9	63
1081	Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer's disease. <i>NeuroImage</i> , 2013 , 66, 28-35	7.9	63
1080	The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, 59	9	63
1079	A paced visual serial addition test for fMRI. <i>Journal of the Neurological Sciences</i> , 2003 , 213, 29-34	3.2	63

1078	Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. <i>European Journal of Human Genetics</i> , 2017 , 25, 973-981	5.3	62
1077	Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015 , 1, 505-12	5.2	62
1076	Increased number of microinfarcts in Alzheimer disease at 7-T MR imaging. <i>Radiology</i> , 2014 , 270, 205-11	20.5	62
1075	Microbleeds do not affect rate of cognitive decline in Alzheimer disease. <i>Neurology</i> , 2012 , 79, 763-9	6.5	62
1074	Does a family meetings intervention prevent depression and anxiety in family caregivers of dementia patients? A randomized trial. <i>PLoS ONE</i> , 2012 , 7, e30936	3.7	62
1073	Cerebral blood flow by using pulsed arterial spin-labeling in elderly subjects with white matter hyperintensities. <i>American Journal of Neuroradiology</i> , 2008 , 29, 1296-301	4.4	62
1072	Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. <i>Molecular Psychiatry</i> , 2017 , 22, 153-160	15.1	61
1071	Plasma Amyloid- β (A β 2) Correlates with Cerebrospinal Fluid A β 2 in Alzheimer's Disease. <i>Journal of Alzheimeris Disease</i> , 2018 , 62, 1857-1863	4.3	61
1070	Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice. <i>PLoS ONE</i> , 2014 , 9, e100784	3.7	61
1069	Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the evaluation of vascular care in Alzheimer's disease (EVA) study. <i>Stroke</i> , 2010 , 41, 554-6	6.7	61
1068	Neurocardiovascular instability, hypotensive episodes, and MRI lesions in neurodegenerative dementia. <i>Annals of the New York Academy of Sciences</i> , 2000 , 903, 442-5	6.5	61
1067	Trajectories of cognitive decline in different types of dementia. <i>Psychological Medicine</i> , 2015 , 45, 1051-96.9		60
1066	Prevalence of cortical superficial siderosis in a memory clinic population. <i>Neurology</i> , 2014 , 82, 698-704	6.5	60
1065	Neuroimaging in Dementia 2011 ,		60
1064	Neurological signs in relation to type of cerebrovascular disease in vascular dementia. <i>Stroke</i> , 2008 , 39, 317-22	6.7	60
1063	Development of a neuropsychological battery for the Leukoaraiosis and Disability in the Elderly Study (LADIS): experience and baseline data. <i>Neuroepidemiology</i> , 2006 , 27, 101-16	5.4	60
1062	Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013 , 34, 2488-94	5.6	59
1061	Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. <i>Alzheimeris and Dementia</i> , 2015 , 11, 1191-201	1.2	59

1060	Discrepancy between subjective and objective sleep disturbances in early- and moderate-stage Alzheimer disease. <i>American Journal of Geriatric Psychiatry</i> , 2012 , 20, 460-7	6.5	59
1059	Diabetes and cognitive impairment. Clinical diagnosis and brain imaging in patients attending a memory clinic. <i>Journal of Neurology</i> , 2006 , 253, 477-82	5.5	59
1058	Anterior medial temporal lobe activation during attempted retrieval of encoded visuospatial scenes: an event-related fMRI study. <i>NeuroImage</i> , 2001 , 14, 67-76	7.9	59
1057	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 235-43	5.5	58
1056	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. <i>JAMA Neurology</i> , 2017 , 74, 1481-1491	17.2	58
1055	Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012 , 33, 627.e1-627.e12	5.6	58
1054	Corpus callosum size correlates with asymmetric performance on a dichotic listening task in healthy aging but not in Alzheimer's disease. <i>Neuropsychologia</i> , 2006 , 44, 208-17	3.2	58
1053	Microvascular disease in type 1 diabetes alters brain activation: a functional magnetic resonance imaging study. <i>Diabetes</i> , 2006 , 55, 334-40	0.9	58
1052	Clinical significance of corpus callosum atrophy in a mixed elderly population. <i>Neurobiology of Aging</i> , 2007 , 28, 955-63	5.6	58
1051	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimeris and Dementia</i> , 2019 , 15, 644-654	1.2	57
1050	Impact of diagnostic disclosure in dementia on patients and carers: qualitative case series analysis. <i>Aging and Mental Health</i> , 2006 , 10, 525-31	3.5	57
1049	Subjective Cognitive Impairment Cohort (SCIENCE): study design and first results. <i>Alzheimeris Research and Therapy</i> , 2018 , 10, 76	9	56
1048	Deterioration of gait and balance over time: the effects of age-related white matter change--the LADIS study. <i>Cerebrovascular Diseases</i> , 2013 , 35, 544-53	3.2	56
1047	Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. <i>Archives of Neurology</i> , 2003 , 60, 1209-13		56
1046	International Work Group criteria for the diagnosis of Alzheimer disease. <i>Medical Clinics of North America</i> , 2013 , 97, 363-8	7	55
1045	Magnetic resonance imaging predictors of cognition in mild cognitive impairment. <i>Archives of Neurology</i> , 2007 , 64, 1023-8		55
1044	Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer's disease and controls. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 49-55	5.2	55
1043	EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. <i>Neurobiology of Aging</i> , 2017 , 57, 133-142	5.6	54

1042	Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2012 , 29, 319-27	4.3	54
1041	Resting-state oscillatory brain dynamics in Alzheimer disease. <i>Journal of Clinical Neurophysiology</i> , 2008 , 25, 187-93	2.2	54
1040	CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 23, 225-30	2.6	54
1039	A neural complexity measure applied to MEG data in Alzheimer's disease. <i>Clinical Neurophysiology</i> , 2003 , 114, 1034-40	4.3	54
1038	Combination of plasma amyloid beta and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 118	9	54
1037	Diffusion changes predict cognitive and functional outcome: the LADIS study. <i>Annals of Neurology</i> , 2013 , 73, 576-83	9.4	53
1036	Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. <i>European Journal of Neurology</i> , 2010 , 17, 90-6	6	53
1035	Frontal lobe dysfunction in unilateral lenticulostriate infarcts. Prominent role of cortical lesions. <i>Archives of Neurology</i> , 1992 , 49, 1285-9		53
1034	Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline. <i>Stroke</i> , 2020 , 51, 170-178	6.7	53
1033	Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. <i>Radiology</i> , 2016 , 279, 838-48	20.5	52
1032	Prevention trials in Alzheimer's disease: an EU-US task force report. <i>Progress in Neurobiology</i> , 2011 , 95, 594-600	10.9	52
1031	Evaluation of reference regions for (R)-[(11)C]PK11195 studies in Alzheimer's disease and mild cognitive impairment. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007 , 27, 1965-74	7.3	52
1030	Application of automated medial temporal lobe atrophy scale to Alzheimer disease. <i>Archives of Neurology</i> , 2007 , 64, 849-54		52
1029	An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 549-55	5	52
1028	MRI and CT in the diagnosis of vascular dementia. <i>Journal of the Neurological Sciences</i> , 2004 , 226, 9-12	3.2	52
1027	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017 , 52, 167-182.e1	5.6	51
1026	White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. <i>Stroke</i> , 2015 , 46, 2661-4	6.7	51
1025	Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: a 3-year follow-up of the LADIS study cohort. <i>Journal of the Neurological Sciences</i> , 2011 , 307, 100-5	3.2	51

1024	Do instrumental activities of daily living predict dementia at 1- and 2-year follow-up? Findings from the Development of Screening guidelines and diagnostic Criteria for Predementia Alzheimer's disease study. <i>Journal of the American Geriatrics Society</i> , 2011 , 59, 2273-81	5.6	51
1023	Test-retest variability of quantitative [¹¹ C]PIB studies in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 36, 1629-38	8.8	51
1022	Cognitive impairment in Alzheimer's disease is modified by APOE genotype. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 24, 98-103	2.6	51
1021	Alzheimer's disease: The state of the art in resting-state magnetoencephalography. <i>Clinical Neurophysiology</i> , 2017 , 128, 1426-1437	4.3	50
1020	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019 , 138, 237-250	14.3	50
1019	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimeris and Dementia</i> , 2019 , 15, 742-753	1.2	50
1018	Dementia: Alzheimer pathology and vascular factors: from mutually exclusive to interaction. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012 , 1822, 340-9	6.9	50
1017	The world of dementia beyond 2020. <i>Journal of the American Geriatrics Society</i> , 2011 , 59, 923-7	5.6	50
1016	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016 , 38, 214.e7-214.e10	5.6	49
1015	Depressive symptoms predict cognitive decline and dementia in older people independently of cerebral white matter changes: the LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 1250-4	5.5	49
1014	Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 760-8	5	49
1013	Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer's Disease. An MEG Study with Virtual Electrodes. <i>Frontiers in Human Neuroscience</i> , 2016 , 10, 238	3.3	49
1012	Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials. <i>Journal of Neurology</i> , 2021 , 268, 1222-1246	5.5	49
1011	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. <i>Brain</i> , 2018 , 141, 3443-3456	11.2	49
1010	Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. <i>Alzheimeris and Dementia</i> , 2015 , 11, 523-32	1.2	48
1009	How golden is the gold standard of neuropathology in dementia?. <i>Alzheimeris and Dementia</i> , 2011 , 7, 486-9	1.2	48
1008	Pathological aging of the brain: an overview. <i>Topics in Magnetic Resonance Imaging</i> , 2004 , 15, 369-89	2.3	48
1007	Safety, tolerability and efficacy of the glutaminy cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. <i>Alzheimeris Research and Therapy</i> , 2018 , 10, 107	9	48

1006	PLD3 variants in population studies. <i>Nature</i> , 2015 , 520, E2-3	50.4	47
1005	Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship. <i>Neurology</i> , 2019 , 93, e334-e346	6.5	47
1004	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 711-20	4.3	47
1003	Validation of the Amsterdam IADL Questionnaire, a new tool to measure instrumental activities of daily living in dementia. <i>Neuroepidemiology</i> , 2013 , 41, 35-41	5.4	47
1002	Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 882-4	5.5	47
1001	Small vessel versus large vessel vascular dementia: risk factors and MRI findings. <i>Journal of Neurology</i> , 2008 , 255, 1644-51; discussion 1813-4	5.5	47
1000	Visual assessment of medical temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry. <i>Psychiatry Research - Neuroimaging</i> , 1999 , 90, 193-9	2.9	47
999	Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. <i>Neuroradiology</i> , 1994 , 36, 382-7	3.2	47
998	Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies. <i>European Radiology</i> , 2014 , 24, 2326-33	8	46
997	Single-subject gray matter graph properties and their relationship with cognitive impairment in early- and late-onset Alzheimer's disease. <i>Brain Connectivity</i> , 2014 , 4, 337-46	2.7	46
996	Microbleeds relate to altered amyloid- β metabolism in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012 , 33, 1011.e1-9	5.6	46
995	Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. <i>European Journal of Neurology</i> , 2000 , 7, 133-44	6	46
994	Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. <i>Alzheimer's and Dementia</i> , 2017 , 13, 1226-1236	1.2	45
993	Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 908-916	5.5	45
992	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , 2019 , 18, 1034-1044	24.1	45
991	Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Frontiers in Human Neuroscience</i> , 2015 , 9, 474	3.3	45
990	Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 511-22	1.2	45
989	Leuko-Araiosis: Relationship with the Types of Focal Lesions Occurring in Acute Cerebrovascular Disorders. <i>Cerebrovascular Diseases</i> , 1992 , 2, 169-176	3.2	45

988	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <i>Brain</i> , 2016 , 139, 2528-39	11.2	45
987	Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017 , 72, 211-221	6.4	44
986	MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 117	5.3	44
985	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. <i>Neurobiology of Aging</i> , 2012 , 33, 1591-8	5.6	44
984	The diagnostic value of magnetic resonance imaging and technetium 99m-HMPAO single-photon-emission computed tomography for the diagnosis of Alzheimer disease in a community-dwelling elderly population. <i>Alzheimer Disease and Associated Disorders</i> , 1997 , 11, 63-70	2.5	44
983	Initial complaints in frontotemporal lobar degeneration. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004 , 17, 302-6	2.6	44
982	Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease: a pilot study. <i>Psychological Medicine</i> , 1999 , 29, 181-7	6.9	44
981	Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. <i>Radiology</i> , 2016 , 281, 865-875	20.5	44
980	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 6, 143-151	5.2	43
979	White matter changes contribute to corpus callosum atrophy in the elderly: the LADIS study. <i>American Journal of Neuroradiology</i> , 2008 , 29, 1498-504	4.4	43
978	Biomarker profiles and their relation to clinical variables in mild cognitive impairment. <i>Neurocase</i> , 2005 , 11, 8-13	0.8	43
977	The transmethylation cycle in the brain of Alzheimer patients. <i>Neuroscience Letters</i> , 2005 , 386, 69-71	3.3	43
976	Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer's disease. <i>Molecular Psychiatry</i> , 2020 , 25, 3380-3398	15.1	43
975	Physical activity in the elderly is associated with improved executive function and processing speed: the LADIS Study. <i>International Journal of Geriatric Psychiatry</i> , 2015 , 30, 744-50	3.9	42
974	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. <i>Neurology</i> , 2014 , 82, 1768-75	6.5	42
973	Associations between patterns of EEG abnormalities and diagnosis in a large memory clinic cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009 , 27, 18-23	2.6	42
972	Understanding higher level gait disturbances in mild dementia in order to improve rehabilitation: 'last in-first out'. <i>Neuroscience and Biobehavioral Reviews</i> , 2011 , 35, 699-714	9	42
971	Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 23, 42-6	2.6	42

970	Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias. <i>Current Opinion in Neurology</i> , 2000 , 13, 391-6	7.1	42
969	Gray matter network disruptions and amyloid beta in cognitively normal adults. <i>Neurobiology of Aging</i> , 2016 , 37, 154-160	5.6	41
968	Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease. <i>Alzheimeris and Dementia</i> , 2012 , 8, 560-3	1.2	41
967	Neuroanatomical and neuropsychological features of elderly euthymic depressed patients with early- and late-onset. <i>Journal of the Neurological Sciences</i> , 2010 , 299, 19-23	3.2	41
966	Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010 , 29, 432-7	2.6	41
965	Thalamic lesions in vascular dementia: low sensitivity of fluid-attenuated inversion recovery (FLAIR) imaging. <i>Stroke</i> , 2004 , 35, 415-9	6.7	41
964	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015 , 36, 2340-7	5.6	40
963	Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study. <i>Journal of Alzheimeris Disease</i> , 2015 , 44, 471-80	4.3	40
962	EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer's disease and controls. <i>Neurobiology of Aging</i> , 2016 , 41, 122-129	5.6	40
961	Subjective Memory Complaints in APOEε4 Carriers are Associated with High Amyloid-β Burden. <i>Journal of Alzheimeris Disease</i> , 2016 , 49, 1115-22	4.3	40
960	Widespread disruption of functional brain organization in early-onset Alzheimer's disease. <i>PLoS ONE</i> , 2014 , 9, e102995	3.7	40
959	Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene. <i>EJNMMI Research</i> , 2012 , 2, 57	3.6	40
958	Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions. <i>Magnetic Resonance Imaging</i> , 1997 , 15, 155-62	3.3	40
957	The role of white matter hyperintensities and medial temporal lobe atrophy in age-related executive dysfunctioning. <i>Brain and Cognition</i> , 2008 , 68, 128-33	2.7	40
956	White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease. <i>Stroke</i> , 2006 , 37, 2248-52	6.7	40
955	L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. <i>Journal of Neural Transmission</i> , 2000 , 107, 183-9	4.3	40
954	A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. <i>Human Brain Mapping</i> , 2017 , 38, 4703-4715	5.9	39
953	Microbleeds, Mortality, and Stroke in Alzheimer Disease: The MISTRAL Study. <i>JAMA Neurology</i> , 2015 , 72, 539-45	17.2	39

952	Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 4, 99-106	5.2	39
951	Blood-based metabolic signatures in Alzheimer's disease. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 196-207	5.2	39
950	CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. <i>Journal of Alzheimeris Disease</i> , 2009 , 16, 601-7	4.3	39
949	Transcranial Doppler blood flow assessment in patients with mild heart failure: correlates with neuroimaging and cognitive performance. <i>Congestive Heart Failure</i> , 2008 , 14, 61-5		39
948	Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects. <i>Journal of Neurology</i> , 2002 , 249, 312-9	5.5	39
947	The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. <i>Alzheimeris Research and Therapy</i> , 2014 , 6, 27	9	38
946	Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. <i>Neurobiology of Aging</i> , 2013 , 34, 73-82	5.6	38
945	Impact commentaries. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 1038-40	5.5	38
944	Progression of Alzheimer disease in Europe: data from the European ICTUS study. <i>Current Alzheimer Research</i> , 2012 , 9, 902-12	3	38
943	Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light--a randomized clinical trial. <i>Trials</i> , 2010 , 11, 19	2.8	38
942	Parametric fMRI analysis of visual encoding in the human medial temporal lobe. <i>Hippocampus</i> , 1999 , 9, 637-43	3.5	38
941	Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 383-391	5.2	37
940	Loss of EEG Network Efficiency Is Related to Cognitive Impairment in Dementia With Lewy Bodies. <i>Movement Disorders</i> , 2015 , 30, 1785-93	7	37
939	Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes. <i>Journal of Alzheimeris Disease</i> , 2016 , 53, 1287-97	4.3	37
938	Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. <i>Journal of Alzheimeris Disease</i> , 2017 , 56, 687-697	4.3	36
937	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid τ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimeris and Dementia</i> , 2018 , 14, 913-924	1.2	36
936	Upward drift in cerebrospinal fluid amyloid τ 2 assay values for more than 10 years. <i>Alzheimeris and Dementia</i> , 2018 , 14, 62-70	1.2	36
935	Pharmacological treatment of dementia: a scoping review of systematic reviews. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013 , 36, 211-28	2.6	36

934	Serum leptin is not altered nor related to cognitive decline in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 44, 809-13	4.3	36
933	More atrophy of deep gray matter structures in frontotemporal dementia compared to Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 44, 635-47	4.3	36
932	Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, 56	9	36
931	Assessment of instrumental activities of daily living in dementia: diagnostic value of the Amsterdam Instrumental Activities of Daily Living Questionnaire. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2013 , 26, 244-50	3.8	36
930	Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial. <i>Journal of Nutrition, Health and Aging</i> , 2011 , 15, 720-4	5.2	36
929	Investigation of resting-state EEG functional connectivity in frontotemporal lobar degeneration. <i>Clinical Neurophysiology</i> , 2008 , 119, 1732-1738	4.3	36
928	White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 104-12	4.6	36
927	Heterogeneity of Alzheimer's disease: consequence for drug trials?. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 122	9	36
926	Unbiased estimates of cerebrospinal fluid β amyloid 1-42 cutoffs in a large memory clinic population. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 8	9	35
925	Eyes-closed task-free electroencephalography in clinical trials for Alzheimer's disease: an emerging method based upon brain dynamics. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 86	9	35
924	New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010 , 30, 1-7	2.6	35
923	Hippocampal atrophy in subcortical vascular dementia. <i>Neurodegenerative Diseases</i> , 2011 , 8, 465-9	2.3	35
922	The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. <i>Alzheimer's and Dementia</i> , 2008 , 4, 255-64	1.2	35
921	Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI study in healthy elderly males. <i>Neuropsychopharmacology</i> , 2006 , 31, 1508-18	8.7	35
920	Improved reliability of hippocampal atrophy rate measurement in mild cognitive impairment using fluid registration. <i>NeuroImage</i> , 2007 , 34, 1036-41	7.9	35
919	Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. <i>Lancet Neurology</i> , 2020 , 19, 699-710	24.1	35
918	Reproducibility of EEG functional connectivity in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 68	9	34
917	Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study. <i>Journal of Neurology</i> , 2013 , 260, 1014-21	5.5	34

916	Amyloid- β oligomers relate to cognitive decline in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 45, 35-43	4.3	34
915	Association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. <i>Neurobiology of Aging</i> , 2012 , 33, 201.e1-8	5.6	34
914	Neuroanatomical and neuropsychological features of euthymic patients with bipolar disorder. <i>American Journal of Geriatric Psychiatry</i> , 2009 , 17, 1012-21	6.5	34
913	Functional connectivity in elderly controls and AD patients using resting state fMRI: a pilot study. <i>Current Alzheimer Research</i> , 2005 , 2, 115-6	3	34
912	Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer's disease pathology. <i>Journal of Neuroinflammation</i> , 2016 , 13, 4	10.1	34
911	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017 , 7, 13333	4.9	33
910	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016 , 46, 235.e1-9	5.6	33
909	Blood pressure and progression of brain atrophy: the SMART-MR Study. <i>JAMA Neurology</i> , 2013 , 70, 1046-53	5.3	33
908	Comparison of the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in differentiating elderly individuals with different degrees of white matter changes. The LADIS Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 24, 73-81	2.6	33
907	Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior. <i>NeuroImage</i> , 2005 , 25, 63-75	7.9	33
906	Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 26-35	5.2	33
905	Assessing Amyloid Pathology in Cognitively Normal Subjects Using F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 541-547	8.9	33
904	Early onset APOE E4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. <i>European Neuropsychopharmacology</i> , 2015 , 25, 1010-7	1.2	32
903	Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Human Brain Mapping</i> , 2016 , 37, 978-88	5.9	32
902	Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016 , 38, 21-31	5.6	32
901	Applying the ATN scheme in a memory clinic population: The ABIDE project. <i>Neurology</i> , 2019 , 93, e1635-61646	6.5	32
900	Single-domain amnesic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013 , 36, 1-19	2.6	32
899	The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. <i>European Journal of Neurology</i> , 2011 , 18, 279-285	6	32

898	EEG abnormalities in early and late onset Alzheimer's disease: understanding heterogeneity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 67-71	5.5	32
897	Quantification of Tau Load Using [F]AV1451 PET. <i>Molecular Imaging and Biology</i> , 2017 , 19, 963-971	3.8	31
896	7T T ₂ -weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015 , 36, 20-6	5.6	31
895	Cerebrovascular and amyloid pathology in prodementia stages: the relationship with neurodegeneration and cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 101	9	31
894	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 64	9	31
893	Cerebrospinal fluid levels of Alzheimer's disease biomarkers in middle-aged patients with type 1 diabetes. <i>Diabetologia</i> , 2014 , 57, 2208-14	10.3	31
892	Reproducibility of quantitative (R)-[11C]verapamil studies. <i>EJNMMI Research</i> , 2012 , 2, 1	3.6	31
891	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015 , 6, 216	4.1	31
890	Young Alzheimer patients show distinct regional changes of oscillatory brain dynamics. <i>Neurobiology of Aging</i> , 2012 , 33, 1008.e25-31	5.6	31
889	Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. <i>Journal of Alzheimer's Disease</i> , 2012 , 29, 459-69	4.3	31
888	Diagnostic accuracy of consensus diagnostic criteria for frontotemporal dementia in a memory clinic population. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 157-64	2.6	31
887	Development of quality indicators for memory clinics. <i>International Journal of Geriatric Psychiatry</i> , 2008 , 23, 119-28	3.9	31
886	Interindividual differences of medial temporal lobe activation during encoding in an elderly population studied by fMRI. <i>NeuroImage</i> , 2004 , 21, 173-80	7.9	31
885	Role of White Matter Lesions in Cognitive Impairment of Vascular Origin. <i>Alzheimer Disease and Associated Disorders</i> , 1999 , 13, S49-54	2.5	31
884	Cognitive reserve moderates long-term cognitive and functional outcome in cerebral small vessel disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1296-1302	5.5	31
883	A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 521-537	4.3	31
882	Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer's disease: Validation in a large memory clinic population. <i>European Radiology</i> , 2017 , 27, 3147-3155	8	30
881	The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study. <i>Psychological Medicine</i> , 2015 , 45, 1509-19	6.9	30

880	ATN classification and clinical progression in subjective cognitive decline: The SCIENCE project. <i>Neurology</i> , 2020 , 95, e46-e58	6.5	30
879	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018 , 3, 463-472	3.4	30
878	BR12-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014 , 35, 1596-604	5.6	30
877	The role of the orbitofrontal cortex in cognition and behavior. <i>Reviews in the Neurosciences</i> , 2015 , 26, 1-11	4.7	30
876	SUCLG2 identified as both a determinant of CSF A β -42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014 , 23, 6644-58	5.6	30
875	Complexity of MRI white matter hyperintensity assessments in relation to cognition in aging and dementia from the Sunnybrook Dementia Study. <i>Journal of Alzheimer's Disease</i> , 2011 , 26 Suppl 3, 379-88 ^{4.3}	4.3	30
874	How useful is the IQCODE for discriminating between Alzheimer's disease, mild cognitive impairment and subjective memory complaints?. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010 , 30, 411-6	2.6	30
873	Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion-weighted and magnetization transfer imaging: the LADIS (Leukoaraiosis and Disability in the Elderly) study. <i>Journal of Magnetic Resonance Imaging</i> , 2009 , 29, 268-74	5.6	30
872	A new rapid landmark-based regional MRI segmentation method of the brain. <i>Journal of the Neurological Sciences</i> , 2002 , 194, 35-40	3.2	30
871	Head trauma and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2002 , 4, 303-8	4.3	30
870	Functional MRI of visual cortex in sedated 18 month-old infants with or without periventricular leukomalacia. <i>Developmental Medicine and Child Neurology</i> , 2001 , 43, 486-90	3.3	30
869	Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 5, 43-52	5.2	30
868	Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer's disease. <i>European Journal of Human Genetics</i> , 2019 , 27, 244-253	5.3	30
867	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 100	9	30
866	Clinical phenotype, atrophy, and small vessel disease in Δ carriers with Alzheimer disease. <i>Neurology</i> , 2018 , 91, e1851-e1859	6.5	30
865	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 61, 75-81	5.6	29
864	Medial temporal lobe atrophy relates more strongly to sleep-wake rhythm fragmentation than to age or any other known risk. <i>Neurobiology of Learning and Memory</i> , 2019 , 160, 132-138	3.1	29
863	Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 9, 76-83	5.2	29

862	Distribution of APOE genotypes in a memory clinic cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 433-8	2.6	29
861	Preliminary results from an MRI/CT-based database for vascular dementia and Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2000 , 903, 542-6	6.5	29
860	A clinical-radiological framework of the right temporal variant of frontotemporal dementia. <i>Brain</i> , 2020 , 143, 2831-2843	11.2	29
859	A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 933-938	6	29
858	An exploratory clinical study of p38 kinase inhibition in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 464-473	5.3	28
857	Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer's Disease. <i>Journal of Alzheimeris Disease</i> , 2015 , 47, 243-52	4.3	28
856	Amyloid and its association with default network integrity in Alzheimer's disease. <i>Human Brain Mapping</i> , 2014 , 35, 779-91	5.9	28
855	Diagnostic impact of CSF biomarkers in a local hospital memory clinic. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010 , 29, 491-7	2.6	28
854	Hippocampal morphometry in population-based incident Alzheimer's disease and vascular dementia: the HAAS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 373-6	5.5	28
853	Evaluation of methods for generating parametric (R-[11C]PK11195 binding images. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007 , 27, 1603-15	7.3	28
852	Attention modulates hemispheric differences in functional connectivity: evidence from MEG recordings. <i>NeuroImage</i> , 2006 , 30, 245-53	7.9	28
851	Evidence for atrophy of the corpus callosum in Alzheimer's disease. <i>European Neurology</i> , 1994 , 34, 83-6	2.1	28
850	Clinical symptoms and risk factors in cerebral microangiopathy patients. <i>PLoS ONE</i> , 2013 , 8, e53455	3.7	28
849	Amyloid-Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 7	5.3	27
848	The sensitivity to change over time of the Amsterdam IADL Questionnaire(). <i>Alzheimeris and Dementia</i> , 2015 , 11, 1231-40	1.2	27
847	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , 2018 , 64, 927-937	5.5	27
846	Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease. <i>Journal of Alzheimeris Disease</i> , 2017 , 55, 1131-1139	4.3	27
845	A nutritional approach to ameliorate altered phospholipid metabolism in Alzheimer's disease. <i>Journal of Alzheimeris Disease</i> , 2014 , 41, 715-7	4.3	27

844	Dementia: the bare essentials. <i>Practical Neurology</i> , 2009 , 9, 241-51	2.4	27
843	Identifying target groups for the prevention of depression among caregivers of dementia patients. <i>International Psychogeriatrics</i> , 2012 , 24, 298-306	3.4	27
842	Whole brain analysis of T2* weighted baseline FMRI signal in dementia. <i>Human Brain Mapping</i> , 2007 , 28, 1313-7	5.9	27
841	Infratentorial abnormalities in vascular dementia. <i>Stroke</i> , 2006 , 37, 105-10	6.7	27
840	Genetic and biochemical markers for Alzheimer's disease: recent developments. <i>Annals of Clinical Biochemistry</i> , 2000 , 37 (Pt 5), 593-607	2.2	27
839	A four-generation Dutch family with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), linked to chromosome 19p13. <i>Clinical Neurology and Neurosurgery</i> , 1995 , 97, 307-13	2	27
838	Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. <i>Journal of prevention of Alzheimer's disease, The</i> , 2017 , 4, 149-156	3.8	27
837	Imaging in Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2009 , 11, 191-9	5.7	27
836	Imaging of Static Brain Lesions in Vascular Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 1999 , 13, S81-90	2.5	27
835	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 112	9	27
834	New insights into the genetic etiology of Alzheimer's disease and related dementias.. <i>Nature Genetics</i> , 2022 ,	36.3	27
833	Discordant amyloid-IPET and CSF biomarkers and its clinical consequences. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 78	9	26
832	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019 , 15, 817-827	1.2	26
831	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. <i>Human Brain Mapping</i> , 2018 , 39, 3143-3151	5.9	26
830	EEG Characteristics of Dementia With Lewy Bodies, Alzheimer's Disease and Mixed Pathology. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 190	5.3	26
829	Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 51	9	26
828	Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. <i>NeuroImage: Clinical</i> , 2015 , 9, 418-29	5.3	26
827	The renin-angiotensin-aldosterone system in cerebral small vessel disease. <i>Journal of Neurology</i> , 2008 , 255, 993-1000	5.5	26

826	Alzheimer's disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid. <i>Journal of Neural Transmission</i> , 2002 , 109, 1203-8	4.3	26
825	CSF markers related to pathogenetic mechanisms in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2002 , 109, 1491-8	4.3	26
824	Arterial stiffness and progression of structural brain changes: The SMART-MR study. <i>Neurology</i> , 2015 , 84, 448-55	6.5	25
823	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2018 , 61, 198-206	5.6	25
822	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 72	9	25
821	Quantitative regional validation of the visual rating scale for posterior cortical atrophy. <i>European Radiology</i> , 2014 , 24, 397-404	8	25
820	(Cost)-effectiveness of family meetings on indicated prevention of anxiety and depressive symptoms and disorders of primary family caregivers of patients with dementia: design of a randomized controlled trial. <i>BMC Geriatrics</i> , 2008 , 8, 2	4.1	25
819	Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline. <i>Frontiers in Psychiatry</i> , 2020 , 11, 585686	5	25
818	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018 , 141, 2895-2907	11.2	25
817	The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. <i>European Journal of Epidemiology</i> , 2018 , 33, 1229-1249	12.1	25
816	Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. <i>Acta Neuropathologica Communications</i> , 2018 , 6, 64	7.3	24
815	Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, S299-305	1.2	24
814	An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. <i>American Journal of Neuroradiology</i> , 2013 , 34, 1550-5	4.4	24
813	Structural neuroimaging58-69		24
812	Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2008 , 23, 387-92	3.9	24
811	Clinically silent dysfunction of dorsal columns and dorsal spinocerebellar tracts in hereditary spastic paraparesis. <i>Journal of the Neurological Sciences</i> , 1994 , 125, 206-11	3.2	24
810	Neuro-imaging in the diagnosis of Alzheimer's disease. I. Computer tomography and magnetic resonance imaging. <i>Clinical Neurology and Neurosurgery</i> , 1992 , 94, 277-89	2	24
809	Dementia and Rapid Mortality: Who is at Risk?. <i>Journal of Alzheimer's Disease</i> , 2016 , 53, 135-42	4.3	24

808	The EMIF-AD PreclinAD study: study design and baseline cohort overview. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 75	9	24
807	Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer's Disease in a Family with Several Generations of APOE-e4 Homozygosity. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 63-74	4.3	23
806	Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 7, 99-106	5.2	23
805	Re-aligning scientific and lay narratives of Alzheimer's disease. <i>Lancet Neurology</i> , 2019 , 18, 918-919	24.1	23
804	Social Cognition Differentiates Behavioral Variant Frontotemporal Dementia From Other Neurodegenerative Diseases and Psychiatric Disorders. <i>American Journal of Geriatric Psychiatry</i> , 2018 , 26, 569-579	6.5	23
803	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2016 , 12, 872-81	1.2	23
802	Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 62	9	23
801	White matter hyperintensities and cognitive impairment during electroconvulsive therapy in severely depressed elderly patients. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 157-66	6.5	23
800	Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014 , 35, 2665-2670	5.6	23
799	Dementia mimicking Alzheimer's disease Owing to a tau mutation: CSF and PET findings. <i>Alzheimer Disease and Associated Disorders</i> , 2010 , 24, 303-7	2.5	23
798	Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2010 , 20, 1083-90	4.3	23
797	Pain intensity and pain affect in relation to white matter changes. <i>Pain</i> , 2006 , 125, 74-81	8	23
796	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021 , 12, 3417	17.4	23
795	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 51, 581-90	4.3	23
794	A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 130-138	6	22
793	The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 959-975	4.3	22
792	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1478-1488	1.2	22
791	Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 33	9	22

790	Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCE project. <i>Neurobiology of Aging</i> , 2019 , 79, 50-58	5.6	22
789	Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1827-1839	4.3	22
788	Influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015 , 36, 1605.e13-20	5.6	22
787	Building a new paradigm for the early recognition of behavioral variant frontotemporal dementia: Late Onset Frontal Lobe Syndrome study. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 735-40	6.5	22
786	Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer's disease: secondary analyses from a randomized, controlled trial. <i>Journal of Nutrition, Health and Aging</i> , 2011 , 15, 672-6	5.2	22
785	EEG functional connectivity and ApoE genotype in Alzheimer's disease and controls. <i>Clinical Neurophysiology</i> , 2008 , 119, 2727-32	4.3	22
784	Shifting paradigms in dementia: toward stratification of diagnosis and treatment using MRI. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1097, 215-24	6.5	22
783	SPM analysis of parametric (R)-[11C]PK11195 binding images: plasma input versus reference tissue parametric methods. <i>NeuroImage</i> , 2007 , 35, 1473-9	7.9	22
782	Sporadic Creutzfeldt-Jakob disease in a young Dutch valine homozygote: atypical molecular phenotype. <i>Annals of Neurology</i> , 2001 , 50, 258-61	9.4	22
781	Small Infarcts in the Centrum ovale: Study of Predisposing Factors. <i>Cerebrovascular Diseases</i> , 1994 , 4, 83-87	3.2	22
780	A Dutch family with autosomal dominant pure spastic paraparesis (Strümpell's disease). <i>Acta Neurologica Scandinavica</i> , 1990 , 82, 169-73	3.8	22
779	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. <i>Alzheimer's and Dementia</i> , 2017 , 13, 903-912	1.2	21
778	The rest-activity rhythm and physical activity in early-onset dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2015 , 29, 45-9	2.5	21
777	Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016 , 41, 210-9	2.6	21
776	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 111	5.3	21
775	Apraxia in mild cognitive impairment and Alzheimer's disease: validity and reliability of the Van Heugten test for apraxia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014 , 38, 55-64	2.6	21
774	The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trial. <i>Trials</i> , 2013 , 14, 305	2.8	21
773	Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2016 , 49, 927-43	4.3	21

772	Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. <i>JMIR Formative Research</i> , 2019 , 3, e13417	2.5	21
771	Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. <i>The Lancet Healthy Longevity</i> , 2021 , 2, e87-e95	9.5	21
770	Effect of Long-Term Vascular Care on Progression of Cerebrovascular Lesions: Magnetic Resonance Imaging Substudy of the PreDIVA Trial (Prevention of Dementia by Intensive Vascular Care). <i>Stroke</i> , 2017 , 48, 1842-1848	6.7	20
769	Aβ4 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. <i>Nature Communications</i> , 2019 , 10, 2240	17.4	20
768	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 73	9	20
767	Comparison of simplified parametric methods for visual interpretation of 11C-Pittsburgh compound-B PET images. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1305-7	8.9	20
766	No mutations in hnRNPA1 and hnRNPA2B1 in Dutch patients with amyotrophic lateral sclerosis, frontotemporal dementia, and inclusion body myopathy. <i>Neurobiology of Aging</i> , 2014 , 35, 1956.e9-1956.e11	5.6	20
765	The structure of the geriatric depressed brain and response to electroconvulsive therapy. <i>Psychiatry Research - Neuroimaging</i> , 2014 , 222, 1-9	2.9	20
764	Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. <i>Alzheimer's and Dementia</i> , 2013 , 9, 276-83	1.2	20
763	Assessing fitness to drive-A validation study on patients with mild cognitive impairment. <i>Traffic Injury Prevention</i> , 2017 , 18, 145-149	1.8	20
762	MEG Beamformer-Based Reconstructions of Functional Networks in Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 107	5.3	20
761	Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study. <i>BMC Neurology</i> , 2012 , 12, 72	3.1	20
760	Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimer's disease with the use of index values. <i>Journal of Alzheimer's Disease</i> , 2010 , 22, 1073-9	4.3	20
759	Corpus callosum tissue loss and development of motor and global cognitive impairment: the LADIS study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 32, 279-86	2.6	20
758	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020 , 95, e1538-e1553	6.5	20
757	Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE genotype. <i>Neurology</i> , 2020 , 95, e2378-e2388	6.5	20
756	Assessing Fitness to Drive in Patients With Different Types of Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2018 , 32, 70-75	2.5	20
755	The plasma peptides of ovarian cancer. <i>Clinical Proteomics</i> , 2018 , 15, 41	5	20

754	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 409	5.3	20
753	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017 , 56, 33-40	5.6	19
752	DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. <i>Epigenomics</i> , 2015 , 7, 533-7	4.4	19
751	Disrupted subject-specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy. <i>Human Brain Mapping</i> , 2016 , 37, 1194-208	5.9	19
750	Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer's disease pathology. <i>Neurobiology of Aging</i> , 2018 , 71, 171-178	5.6	19
749	Predicting progression from cognitive impairment to Alzheimer's disease with the Disease State Index. <i>Current Alzheimer Research</i> , 2015 , 12, 69-79	3	19
748	Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population. <i>Journal of Alzheimer's Disease</i> , 2013 , 36, 79-85	4.3	19
747	Progression to dementia in memory clinic patients without dementia: a latent profile analysis. <i>Neurology</i> , 2013 , 81, 1342-9	6.5	19
746	Evaluation of tracer kinetic models for analysis of [18F]FDDNP studies. <i>Molecular Imaging and Biology</i> , 2009 , 11, 322-33	3.8	19
745	Low vitamin B6 levels are associated with white matter lesions in Alzheimer's disease. <i>Journal of the American Geriatrics Society</i> , 2005 , 53, 1073-4	5.6	19
744	Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005 , 19, 126-33	2.6	19
743	Blood pressure, white matter lesions and medial temporal lobe atrophy: closing the gap between vascular pathology and Alzheimer's disease?. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005 , 20, 331-7	2.6	19
742	Neuro-imaging in the diagnosis of Alzheimer's disease. II. Positron and single photon emission tomography. <i>Clinical Neurology and Neurosurgery</i> , 1993 , 95, 81-91	2	19
741	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , 2019 , 15, 388-399	1.2	19
740	Auditory hallucinations in adults with hearing impairment: a large prevalence study. <i>Psychological Medicine</i> , 2019 , 49, 132-139	6.9	19
739	CSF ApoE predicts clinical progression in nondemented APOE $\epsilon\epsilon$ carriers. <i>Neurobiology of Aging</i> , 2017 , 57, 186-194	5.6	18
738	Glutaminy cyclase activity correlates with levels of A β peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 38	9	18
737	Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. <i>American Journal of Geriatric Psychiatry</i> , 2015 , 23, 1056-66	6.5	18

736	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. <i>Acta Neuropathologica</i> , 2020 , 139, 1025-1044	14.3	18
735	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCE project. <i>Neurobiology of Aging</i> , 2020 , 89, 99-107	5.6	18
734	Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. <i>Neurobiology of Aging</i> , 2018 , 61, 238-244	5.6	18
733	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 67	5.3	18
732	Associations between quantitative [F]lortaucipir tau PET and atrophy across the Alzheimer's disease spectrum. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 60	9	18
731	Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia. <i>BMC Neuroscience</i> , 2012 , 13, 85	3.2	18
730	A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2013 , 9, 262-8	1.2	18
729	Associations between magnetic resonance imaging measures and neuropsychological impairment in early and late onset alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2013 , 35, 169-78	4.3	18
728	Self-perceived memory complaints predict progression to Alzheimer disease. The LADIS study. <i>Journal of Alzheimer's Disease</i> , 2011 , 27, 491-8	4.3	18
727	Clinical characteristics of patients with frontotemporal dementia with and without lobar atrophy on MRI. <i>Alzheimer Disease and Associated Disorders</i> , 2010 , 24, 242-7	2.5	18
726	Revised research diagnostic criteria for Alzheimer's disease. <i>Lancet Neurology</i> , 2008 , 7, 668-70	24.1	18
725	Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 26, 522-7	2.6	18
724	Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease. <i>Scientific Reports</i> , 2021 , 11, 9736	4.9	18
723	Low Prevalence of Mixed Dementia in a Cohort of 2,000 Elderly Patients in a Memory Clinic Setting. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 797-806	4.3	18
722	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2018 , 19, 625-632	5.3	18
721	Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 139-146	5.2	17
720	White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study. <i>Journal of the American Geriatrics Society</i> , 2019 , 67, 1827-1834	5.6	17
719	The metabolic syndrome in a memory clinic population: relation with clinical profile and prognosis. <i>Journal of the Neurological Sciences</i> , 2015 , 351, 18-23	3.2	17

718	Fingerprinting Alzheimer's Disease by H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. <i>Journal of Proteome Research</i> , 2020 , 19, 1696-1705	5.6	17
717	Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1037-1047	5.3	17
716	Neuroinflammation is increased in the parietal cortex of atypical Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2018 , 15, 170	10.1	17
715	The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. <i>Alzheimer's Research and Therapy</i> , 2014 , 6, 47	9	17
714	Directional information flow in patients with Alzheimer's disease. A source-space resting-state MEG study. <i>NeuroImage: Clinical</i> , 2017 , 15, 673-681	5.3	17
713	Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011 , 50, 61-5	5.9	17
712	Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 1145-8	5.5	17
711	Increase in cerebrospinal fluid F2-isoprostanes is related to cognitive decline in APOE ϵ carriers. <i>Journal of Alzheimer's Disease</i> , 2013 , 36, 563-70	4.3	17
710	Quantification of amyloid-beta 40 in cerebrospinal fluid. <i>Journal of Immunological Methods</i> , 2009 , 348, 57-66	2.5	17
709	EEG abnormalities are associated with different cognitive profiles in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 31, 1-6	2.6	17
708	Diagnosing Alzheimer's disease in community-dwelling elderly: a comparison of EEG and MRI. <i>Dementia and Geriatric Cognitive Disorders</i> , 1997 , 8, 198-202	2.6	17
707	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. <i>Nature Reviews Neuroscience</i> , 2021 ,	13.5	17
706	ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. <i>Nature Aging</i> , 2021 , 1, 521-534		17
705	PET and CSF amyloid- β status are differently predicted by patient features: information from discordant cases. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 100	9	17
704	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019 , 40, 638-651	5.9	17
703	Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. <i>Brain</i> , 2018 , 141, 3377-3388	11.2	17
702	A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/A β 2 cutoff with concordance to amyloid positron emission tomography imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 6, 201-209	5.2	16
701	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 74	9	16

700	Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. <i>Nutrients</i> , 2019 , 11,	6.7	16
699	EEG-based neurophysiological indicators of hallucinations in Alzheimer's disease: Comparison with dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2018 , 67, 75-83	5.6	16
698	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. <i>Neurobiology of Aging</i> , 2019 , 84, 225-234	5.6	16
697	Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β peptide. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013 , 20, 179-87	2.7	16
696	Exercise and early-onset Alzheimer's disease: theoretical considerations. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012 , 2, 132-45	2.5	16
695	Distortions in rest-activity rhythm in aging relate to white matter hyperintensities. <i>Neurobiology of Aging</i> , 2008 , 29, 1265-71	5.6	16
694	The impact of diagnostic disclosure in dementia: a qualitative case analysis. <i>International Psychogeriatrics</i> , 2005 , 17, 319-26	3.4	16
693	Effectiveness of family meetings for family caregivers on delaying time to nursing home placement of dementia patients: a randomized trial. <i>PLoS ONE</i> , 2012 , 7, e42145	3.7	16
692	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020 , 143, 3776-3792	11.2	16
691	Association of amyloid- β /CSF/PET discordance and tau load 5 years later. <i>Neurology</i> , 2020 , 95, e2648-e2657	5.5	16
690	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. <i>Alzheimeris and Dementia</i> , 2020 , 16, 1457-1468	1.2	16
689	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. <i>Journal of Alzheimeris Disease</i> , 2017 , 60, 1387-1395	4.3	15
688	Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy. <i>Journal of Alzheimeris Disease</i> , 2015 , 44, 153-62	4.3	15
687	Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. <i>Neurology</i> , 2018 , 90, e877-e886	6.5	15
686	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. <i>Alzheimeris and Dementia</i> , 2018 , 14, 837-842	1.2	15
685	Validation of soluble amyloid- β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2016 , 137, 112-21	6	15
684	Quantification of [18 F]florbetapir: A test-retest tracer kinetic modelling study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019 , 39, 2172-2180	7.3	15
683	Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 463-471	5.2	15

682	Dysglycemia, brain volume and vascular lesions on MRI in a memory clinic population. <i>Journal of Diabetes and Its Complications</i> , 2014 , 28, 85-90	3.2	15
681	Psychosis in behavioral variant frontotemporal dementia. <i>Neuropsychiatric Disease and Treatment</i> , 2017 , 13, 1099-1106	3.1	15
680	No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012 , 32, 1468-71	7.3	15
679	Cognitive impairment no dementia - neuropsychological and neuroimaging characterization of an amnesic subgroup. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 238-47	2.6	15
678	Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders. <i>Clinical Chemistry</i> , 2006 , 52, 1604-6	5.5	15
677	Effects of transcutaneous electrical nerve stimulation (TENS) on non-pain related cognitive and behavioural functioning. <i>Reviews in the Neurosciences</i> , 2002 , 13, 257-70	4.7	15
676	Pre-and post-mortem MR imaging of unsuspected multiple sclerosis in a patient with Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 1993 , 117, 175-8	3.2	15
675	Serial quantitative MR assessment of optic neuritis in a case of neuromyelitis optica, using Gadolinium- "enhanced" STIR imaging. <i>Neuroradiology</i> , 1991 , 33, 70-1	3.2	15
674	Methotrexate induced brain necrosis and severe leukoencephalopathy due to disconnection of an Ommaya device. <i>Journal of Neuro-Oncology</i> , 1993 , 15, 269-73	4.8	15
673	Cognitive Deficits in Patients With Neuropsychiatric Symptoms: A Comparative Study Between Behavioral Variant Frontotemporal Dementia and Primary Psychiatric Disorders. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, e940-e946	4.6	15
672	The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 679-689	4.3	15
671	In vivo tau pathology is associated with synaptic loss and altered synaptic function. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 35	9	15
670	A novel partial volume correction method for accurate quantification of [F] flortaucipir in the hippocampus. <i>EJNMMI Research</i> , 2018 , 8, 79	3.6	15
669	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. <i>BMC Geriatrics</i> , 2018 , 18, 289	4.1	15
668	The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer's Disease. <i>Brain Connectivity</i> , 2016 , 6, 1-8	2.7	14
667	Low normal cerebrospinal fluid A β 2 levels predict clinical progression in nondemented subjects. <i>Annals of Neurology</i> , 2017 , 81, 749-753	9.4	14
666	Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020 , 95, e662-e670	6.5	14
665	Alzheimer's disease patients not carrying the apolipoprotein E ϵ 4 allele show more severe slowing of oscillatory brain activity. <i>Neurobiology of Aging</i> , 2013 , 34, 2158-63	5.6	14

664	The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 513-523	6	14
663	Increased skin temperature in Alzheimer's disease is associated with sleepiness. <i>Journal of Neural Transmission</i> , 2012 , 119, 1185-94	4.3	14
662	Moving forward with nutrition in Alzheimer's disease. <i>European Journal of Neurology</i> , 2009 , 16 Suppl 1, 19-22	6	14
661	The effect of anxiety and depression on decline of memory function in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2009 , 21, 1142-7	3.4	14
660	White matter hyperintensities and working memory: an explorative study. <i>Aging, Neuropsychology, and Cognition</i> , 2008 , 15, 384-99	2.1	14
659	Diagnostic tools for the study of vascular cognitive dysfunction in hypertension and antihypertensive drug research 2006 , 109, 274-83		14
658	In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease. <i>Clinical Neurophysiology</i> , 2020 , 131, 88-95	4.3	14
657	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019 , 22, 101786	5.3	13
656	APOE ϵ genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimeris Research and Therapy</i> , 2020 , 12, 65	9	13
655	Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. <i>Alzheimeris Research and Therapy</i> , 2018 , 10, 23	9	13
654	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. <i>Alzheimeris Research and Therapy</i> , 2018 , 10, 58	9	13
653	Clinician-patient communication during the diagnostic workup: The ABIDE project. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 520-528	5.2	13
652	Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. <i>Journal of Neurology</i> , 2014 , 261, 1160-9	5.5	13
651	Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. <i>Acta Neuropathologica Communications</i> , 2014 , 2, 79	7.3	13
650	Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. <i>Alzheimeris and Dementia</i> , 2013 , 9, 269-75	1.2	13
649	DT-01-03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road global, multicenter trial 2015 , 11, P331-P332		13
648	Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010 , 31, 539-40; author reply 541	5.6	13
647	Regional differences in effects of APOE ϵ on cognitive impairment in non-demented subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 32, 135-42	2.6	13

646	Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008 , 46, 1300-4	5.9	13
645	Progressive, isolated language disturbance: its significance in a 65-year-old-man. A case report with implications for treatment and review of literature. <i>Journal of the Neurological Sciences</i> , 2006 , 240, 45-51	3.2	13
644	Vascular dementia: the role of cerebral infarcts. <i>Alzheimer Disease and Associated Disorders</i> , 1999 , 13 Suppl 3, S38-48	2.5	13
643	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. <i>Neurology</i> , 2020 , 95, e3026-e3035	6.5	13
642	The Diagnostic Challenge of the Late-Onset Frontal Lobe Syndrome: Clinical Predictors for Primary Psychiatric Disorders Versus Behavioral Variant Frontotemporal Dementia. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, e1197-e1203	4.6	13
641	ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF A β 2, levels in non-demented elderly. <i>Neurobiology of Aging</i> , 2019 , 79, 101-109	5.6	12
640	Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation. <i>Lecture Notes in Computer Science</i> , 2016 , 87-96	0.9	12
639	Evaluating combinations of diagnostic tests to discriminate different dementia types. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 509-518	5.2	12
638	Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. <i>Alzheimeris and Dementia</i> , 2014 , 10, 456-467	1.2	12
637	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. <i>Journal of Alzheimeris Disease</i> , 2016 , 50, 261-70	4.3	12
636	Study protocol: EXERcise and cognition in sedentary adults with early-ONset dementia (EXERCISE-ON). <i>BMC Neurology</i> , 2012 , 12, 75	3.1	12
635	Utility of imaging for nutritional intervention studies in Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2011 , 668 Suppl 1, S59-69	5.3	12
634	Validation of the HIV Dementia Scale in an elderly cohort of patients with subcortical cognitive impairment caused by subcortical ischaemic vascular disease or a normal pressure hydrocephalus. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004 , 18, 109-14	2.6	12
633	Intracerebral haemorrhage in Sneddon's syndrome. <i>Journal of the Neurological Sciences</i> , 1992 , 111, 227-8	3.2	12
632	Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , 2020 , 21, 1513.e1-1513.e17	5.9	12
631	Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. <i>Acta Neuropathologica Communications</i> , 2014 , 2, 79	7.3	12
630	SORL1 deficiency in human excitatory neurons causes APP-dependent defects in the endolysosome-autophagy network. <i>Cell Reports</i> , 2021 , 35, 109259	10.6	12
629	A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands. <i>BMC Neurology</i> , 2016 , 16, 242	3.1	12

628	High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. <i>Neuropsychologia</i> , 2019 , 131, 184-192	3.2	11
627	Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 45	9	11
626	Automatically computed rating scales from MRI for patients with cognitive disorders. <i>European Radiology</i> , 2019 , 29, 4937-4947	8	11
625	A Suboptimal Diet is Associated with Poorer Cognition: The NUDAD Project. <i>Nutrients</i> , 2020 , 12,	6.7	11
624	Regional [F]lortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2866-2878	8.8	11
623	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1458-1467	1.2	11
622	Hypertensive Disorders of Pregnancy Appear Not to Be Associated with Alzheimer's Disease Later in Life. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015 , 5, 375-85	2.5	11
621	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 889-99	4.3	11
620	Improving the accuracy and precision of cognitive testing in mild dementia. <i>Journal of the International Neuropsychological Society</i> , 2012 , 18, 314-22	3.1	11
619	No evidence for increased self-reported cognitive failure in Type 1 and Type 2 diabetes: a cross-sectional study. <i>Diabetic Medicine</i> , 2007 , 24, 735-40	3.5	11
618	Progressive dementia and mesiotemporal atrophy on brain MRI: neurosyphilis mimicking pre-senile Alzheimer's disease?. <i>European Journal of Neurology</i> , 2008 , 15, e14-5	6	11
617	Peripheral electrical nerve stimulation and rest-activity rhythm in Alzheimer's disease. <i>Journal of Sleep Research</i> , 2006 , 15, 415-23	5.8	11
616	Relationships between white matter hyperintensities, cerebral amyloid angiopathy and dementia in a population-based sample of the oldest old. <i>Current Alzheimer Research</i> , 2013 , 10, 1090-7	3	11
615	Associations Between Caffeine Consumption, Cognitive Decline, and Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2020 , 78, 1519-1546	4.3	11
614	Parametric methods for [F]lortaucipir PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020 , 40, 365-373	7.3	11
613	Olfactory and gustatory functioning and food preferences of patients with Alzheimer's disease and mild cognitive impairment compared to controls: the NUDAD project. <i>Journal of Neurology</i> , 2020 , 267, 144-152	5.5	11
612	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020 , 16, 750-758	1.2	11
611	The plasma peptidome. <i>Clinical Proteomics</i> , 2018 , 15, 39	5	11

610	Multiple diagnostic tests are needed to assess multiple causes of dementia. <i>Archives of Neurology</i> , 2006 , 63, 144-6		11
609	Early-Onset Dementia: Frequency, Diagnostic Procedures, and Quality Indicators in Three European Tertiary Referral Centers. <i>Alzheimer Disease and Associated Disorders</i> , 2017 , 31, 146-151	2.5	10
608	Gray matter T1-w/T2-w ratios are higher in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019 , 40, 3900-3909	3.9	10
607	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimeris Disease</i> , 2020 , 74, 213-225	4.3	10
606	Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 3165-3175	8.8	10
605	Education as Proxy for Cognitive Reserve in a Large Elderly Memory Clinic: 'Window of Benefit'. <i>Journal of Alzheimeris Disease</i> , 2020 , 76, 671-679	4.3	10
604	Effectiveness of Pharmacological Interventions for Symptoms of Behavioral Variant Frontotemporal Dementia: A Systematic Review. <i>Cognitive and Behavioral Neurology</i> , 2020 , 33, 1-15	1.6	10
603	Structural neuroimaging of Alzheimer's disease and other dementias. <i>Aging Clinical and Experimental Research</i> , 2001 , 13, 203-9	4.8	10
602	Clinical neurophysiology in the diagnosis of Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> , 1994 , 96, 111-8	2	10
601	Amyloid- β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. <i>Alzheimeris Research and Therapy</i> , 2020 , 12, 169	9	10
600	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6. <i>Alzheimeris Research and Therapy</i> , 2021 , 13, 169	9	10
599	Immune response and endocytosis pathways are associated with the resilience against Alzheimer's disease. <i>Translational Psychiatry</i> , 2020 , 10, 332	8.6	10
598	Amyloid-IPET and CSF in an autopsy-confirmed cohort. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 2150-2160	5.3	10
597	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020 , 10, 403	8.6	10
596	Neuropsychological Test Performance of Cognitively Healthy Centenarians: Normative Data From the Dutch 100-Plus Study. <i>Journal of the American Geriatrics Society</i> , 2019 , 67, 759-767	5.6	10
595	Impairment in complex activities of daily living is related to neurodegeneration in Alzheimer's disease-specific regions. <i>Neurobiology of Aging</i> , 2019 , 75, 109-116	5.6	10
594	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2021 , 27, 426-438	3.1	10
593	Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCE Project. <i>Nutrients</i> , 2019 , 11,	6.7	9

592	Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. <i>Neurobiology of Aging</i> , 2019 , 77, 58-65	5.6	9
591	White matter hyperintensities and vascular risk factors in monozygotic twins. <i>Neurobiology of Aging</i> , 2018 , 66, 40-48	5.6	9
590	Understanding hallucinations in probable Alzheimer's disease: Very low prevalence rates in a tertiary memory clinic. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 358-362	5.2	9
589	A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibility. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 153-160	5.2	9
588	Cortical phase changes measured using 7-T MRI in subjects with subjective cognitive impairment, and their association with cognitive function. <i>NMR in Biomedicine</i> , 2016 , 29, 1289-94	4.4	9
587	Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression. <i>Journal of Alzheimeris Disease</i> , 2018 , 65, 1029-1039	4.3	9
586	Survival in memory clinic cohort is short, even in young-onset dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 726-728	5.5	9
585	Lumbar puncture in patients with neurologic conditions. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 108-110	5.2	9
584	Progression from MCI to AD: predictive value of CSF A β 2 is modified by APOE genotype. <i>Neurobiology of Aging</i> , 2011 , 32, 1372-8	5.6	9
583	Association between vitamin B6 and white matter hyperintensities in patients with Alzheimer's disease not mediated by homocysteine metabolism. <i>Journal of the American Geriatrics Society</i> , 2007 , 55, 956-8	5.6	9
582	The auditory oddball paradigm in patients with vascular cognitive impairment: a prolonged latency of the N2 complex. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006 , 21, 322-7	2.6	9
581	Effects of high-frequency cranial electrostimulation on the rest-activity rhythm and salivary cortisol in Alzheimer's disease: a pilot study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006 , 22, 267-72	2.6	9
580	White-matter changes on MRI as surrogate marker. <i>International Psychogeriatrics</i> , 2003 , 15 Suppl 1, 261-5	3.4	9
579	Cerebrospinal fluid tau levels in frontotemporal dementia. <i>Annals of Neurology</i> , 2005 , 58, 656-7; author reply 657	9.4	9
578	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , 2022 ,	17.2	9
577	Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: the NUDAD project. <i>Alzheimeris Research and Therapy</i> , 2020 , 12, 116	9	9
576	Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. <i>Neurology</i> , 2020 , 95, e1672-e1685	6.5	9
575	The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12021	5.2	9

574	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. <i>Alzheimeris and Dementia</i> , 2021 , 17, 1189-1204	1.2	9
573	Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia. <i>Journal of Alzheimeris Disease</i> , 2016 , 51, 1249-56	4.3	9
572	Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways 2000 , 10, 398		9
571	Driving Difficulties Among Patients with Alzheimer's Disease and Other Neurodegenerative Disorders. <i>Journal of Alzheimeris Disease</i> , 2019 , 69, 1019-1030	4.3	8
570	Imaging biomarkers in Alzheimer's disease: added value in the clinical setting. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 61, 360-371	1.4	8
569	Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016 , 41, 16-26	2.6	8
568	Glycemia and levels of cerebrospinal fluid amyloid and tau in patients attending a memory clinic. <i>Journal of the American Geriatrics Society</i> , 2010 , 58, 1318-21	5.6	8
567	Subcortical white matter pathology as a mediating factor for age-related decreased performance in dichotic listening. <i>Neuropsychologia</i> , 2007 , 45, 2322-32	3.2	8
566	Nonlinear changes in brain activity during continuous word repetition: an event-related multiparametric functional MR imaging study. <i>American Journal of Neuroradiology</i> , 2007 , 28, 1715-21	4.4	8
565	Differences and similarities between two frequently used assays for amyloid beta 42 in cerebrospinal fluid. <i>Clinical Chemistry</i> , 2005 , 51, 1057-60	5.5	8
564	Cooperation and networking on white matter disorders: the European Task Force on Age-Related White Matter Changes. <i>Dementia and Geriatric Cognitive Disorders</i> , 1998 , 9 Suppl 1, 44-5	2.6	8
563	Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services-part 4 of 6. <i>Alzheimeris Research and Therapy</i> , 2021 , 13, 171	9	8
562	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	8
561	Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. <i>Neurology</i> , 2021 , 96, e2673-e2684	6.5	8
560	A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease. <i>Alzheimeris Research and Therapy</i> , 2021 , 13, 106	9	8
559	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. <i>EMBO Molecular Medicine</i> , 2021 , 13, e14398	12	8
558	The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. <i>Journal of Alzheimeris Disease</i> , 2019 , 68, 311-322	4.3	8
557	Can MRI be used as a proxy for ? A case study. <i>Brain Communications</i> , 2019 , 1, fcz030	4.5	8

556	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 1-9	5.2	8
555	The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , 2020 , 6, e12020	6	8
554	Computer-assisted prediction of clinical progression in the earliest stages of AD. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 726-736	5.2	8
553	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations. <i>Neurology</i> , 2021 , 97, e1276-e1287	6.5	8
552	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimeris Disease</i> , 2017 , 56, 543-555	4.3	7
551	Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. <i>Neurology</i> , 2019 , 92, e2699-e2705	6.5	7
550	Longitudinal Maintenance of Cognitive Health in Centenarians in the 100-plus Study. <i>JAMA Network Open</i> , 2020 , 3, e200094	10.4	7
549	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 1190-8	8.8	7
548	White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 213	5.3	7
547	Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort. <i>Journal of Neurology</i> , 2014 , 261, 2085-92	5.5	7
546	Confirmatory factor analysis of the Neuropsychological Assessment Battery of the LADIS study: a longitudinal analysis. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013 , 35, 269-78	2.1	7
545	CSF levels of PSA and PSA-ACT complexes in Alzheimer's disease. <i>Annals of Clinical Biochemistry</i> , 2009 , 46, 477-83	2.2	7
544	Dementia in 2011: Microbleeds in dementia--singing a different ARIA. <i>Nature Reviews Neurology</i> , 2012 , 8, 68-70	15	7
543	Research Criteria for the Behavioral Variant of Alzheimer Disease: A Systematic Review and Meta-analysis. <i>JAMA Neurology</i> , 2021 ,	17.2	7
542	Gut Microbiota Composition Is Related to AD Pathology.. <i>Frontiers in Immunology</i> , 2021 , 12, 794519	8.4	7
541	Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesionSymptom mapping study. <i>Journal of Psychiatry and Neuroscience</i> , 2019 , 44, E1-E10	4.5	7
540	The Alzheimer's disease drug development landscape. <i>Alzheimeris Research and Therapy</i> , 2021 , 13, 186	9	7
539	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020 , 94, 71-80	5.6	7

538	Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort. <i>Journal of Alzheimeris Disease</i> , 2016 , 52, 875-85	4.3	7
537	Cognitive functioning of individuals aged 90 years and older without dementia: A systematic review. <i>Ageing Research Reviews</i> , 2017 , 36, 42-49	12	6
536	Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease: protocol of the BEAT-IT study. <i>Alzheimeris Research and Therapy</i> , 2019 , 11, 48	9	6
535	Rethinking biobanking and translational medicine in the Netherlands: how the research process stands to matter for patient care. <i>European Journal of Human Genetics</i> , 2015 , 23, 736-8	5.3	6
534	Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2020 , 93, 144.e1-144.e15	5.6	6
533	Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. <i>Journal of Alzheimeris Disease</i> , 2017 , 60, 201-210	4.3	6
532	Cerebral White Matter Lesions have Low Impact on Cognitive Function in a Large Elderly Memory Clinic Population. <i>Journal of Alzheimeris Disease</i> , 2018 , 63, 1129-1139	4.3	6
531	Role of Vascular Disease in Alzheimer-Like Progressive Cognitive Impairment. <i>Stroke</i> , 2016 , 47, 577-80	6.7	6
530	Added value of amyloid PET in individualized risk predictions for MCI patients. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 529-537	5.2	6
529	Cognitive and functional progression of dementia in two longitudinal studies. <i>International Journal of Geriatric Psychiatry</i> , 2019 , 34, 1623-1632	3.9	6
528	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019 , 266, 2535-2545	5.5	6
527	The association between APOE ϵ 4 and Alzheimer-type dementia among memory clinic patients is confined to those with a higher education. The DESCRIPA Study. <i>Journal of Alzheimeris Disease</i> , 2013 , 35, 241-6	4.3	6
526	New lexicon and criteria for the diagnosis of Alzheimer's disease [Authors' reply]. <i>Lancet Neurology</i> , 2011 , 10, 300-301	24.1	6
525	Autosomal recessive paraparesis with amyotrophy of the hands and feet. <i>Acta Neurologica Scandinavica</i> , 1993 , 87, 443-5	3.8	6
524	Protocols for cognitive enhancement. A user manual for Brain Health Services-part 5 of 6. <i>Alzheimeris Research and Therapy</i> , 2021 , 13, 172	9	6
523	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services-part 1 of 6. <i>Alzheimeris Research and Therapy</i> , 2021 , 13, 168	9	6
522	Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI. <i>Alzheimeris Research and Therapy</i> , 2020 , 12, 10	9	6
521	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. <i>Alzheimeris Research and Therapy</i> , 2020 , 12, 8	9	6

520	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. <i>Brain Communications</i> , 2020 , 2, fcaa102	4.5	6
519	Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 148	9	6
518	Frontotemporal dementia, music perception and social cognition share neurobiological circuits: A meta-analysis. <i>Brain and Cognition</i> , 2021 , 148, 105660	2.7	6
517	Plasma amyloid- β oligomerization assay as a pre-screening test for amyloid status. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 133	9	6
516	Magnetoencephalography for the Detection of Intervention Effects of a Specific Nutrient Combination in Patients with Mild Alzheimer's Disease: Results from an Exploratory Double-Blind, Randomized, Controlled Study. <i>Frontiers in Neurology</i> , 2016 , 7, 161	4.1	6
515	The plasma peptides of breast versus ovarian cancer. <i>Clinical Proteomics</i> , 2019 , 16, 43	5	6
514	Dutch Brain Research Registry for study participant recruitment: Design and first results. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021 , 7, e12132	6	6
513	Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , 2020 ,	5.9	5
512	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 138	9	5
511	Cognitive Decline in Patients with Chronic Hydrocephalus and Normal Aging: 'Growing into Deficits'. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016 , 6, 500-507	2.5	5
510	Microbleeds are associated with depressive symptoms in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 112-120	5.2	5
509	Schizophrenia as a mimic of behavioral variant frontotemporal dementia. <i>Neurocase</i> , 2016 , 22, 285-8	0.8	5
508	An intervention programme for caregivers of dementia patients with frontal behavioural changes: an explorative study with controlled effect on sense of competence. <i>Psychogeriatrics</i> , 2018 , 18, 451-459	1.8	5
507	Amyloid- β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 83	9	5
506	A novel CCM2 variant in a family with non-progressive cognitive complaints and cerebral microbleeds. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017 , 174, 220-226	3.5	5
505	Normal Ageing 2011 , 43-57		5
504	Simplified parametric methods for [18F]FDDNP studies. <i>NeuroImage</i> , 2010 , 49, 433-41	7.9	5
503	Multi-center comparison of medial temporal atrophy in patients with Alzheimer's disease--data from the ICTUS study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 26, 314-22	2.6	5

502	Use of proteomic approaches to identify disease biomarkers. <i>Lancet Neurology, The</i> , 2007 , 6, 1036-7	24.1	5
501	White-matter lesions on CT in Alzheimer patients. <i>Acta Neurologica Scandinavica</i> , 1991 , 84, 264-5	3.8	5
500	Anterolateral lumbar meningocele presenting as an ovarian cyst, in a patient with neurofibromatosis. <i>Clinical Neurology and Neurosurgery</i> , 1989 , 91, 351-4	2	5
499	Dementia risk communication. A user manual for Brain Health Services-part 3 of 6. <i>Alzheimeris Research and Therapy</i> , 2021 , 13, 170	9	5
498	The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description		5
497	Why Is Amyloid-IPET Requested After Performing CSF Biomarkers?. <i>Journal of Alzheimeris Disease</i> , 2020 , 73, 559-569	4.3	5
496	Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12063	5.2	5
495	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. <i>Annals of Neurology</i> , 2021 , 89, 987-1000	9.4	5
494	P2-131: Applying Random Forest Machine Learning to Diagnose Alzheimer's Disease and Dementia with Lewy Bodies: A Combination of Electroencephalography (EEG), Clinical Parameters and Biomarkers 2016 , 12, P661-P662		5
493	Predicting progression in the late onset frontal lobe syndrome. <i>International Psychogeriatrics</i> , 2019 , 31, 743-748	3.4	5
492	Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60-102 Years. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020 , 75, 1609-1617	6.4	5
491	Association of Cognitive Function Trajectories in Centenarians With Postmortem Neuropathology, Physical Health, and Other Risk Factors for Cognitive Decline. <i>JAMA Network Open</i> , 2021 , 4, e2031654	10.4	5
490	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. <i>Alzheimeris Research and Therapy</i> , 2021 , 13, 2	9	5
489	Visual assessment of [F]flutemetamol PET images can detect early amyloid pathology and grade its extent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2169-2182	8.8	5
488	The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series. <i>Journal of Alzheimeris Disease</i> , 2021 , 79, 1195-1201	4.3	5
487	What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. <i>journal of prevention of Alzheimeris disease, The</i> , 2018 , 5, 171-174	3.8	5
486	Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs. <i>Journal of Nutrition, Health and Aging</i> , 2006 , 10, 123-8; discussion 129-30	5.2	5
485	Cerebrospinal fluid collection: An informative animation video for patients and caregivers. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 435-438	5.2	4

484	How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 1273-1286	4.3	4
483	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE ϵ carriers. <i>Scientific Reports</i> , 2020 , 10, 8233	4.9	4
482	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , 2020 , 76, 1061-1070	4.3	4
481	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. <i>PLoS ONE</i> , 2020 , 15, e0226784	3.7	4
480	Does MRI Increase the Diagnostic Confidence of Physicians in an Outpatient Memory Clinic. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016 , 6, 242-51	2.5	4
479	Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018 , 8, 455-462	5.3	4
478	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 492-500	6	4
477	Medical Clinics of North America. Early diagnosis and intervention in predementia Alzheimer's disease. Preface. <i>Medical Clinics of North America</i> , 2013 , 97, xiii-xv	7	4
476	[O20203]: DURATION OF ALZHEIMER'S DISEASE IN THE PRECLINICAL, PRODROMAL AND DEMENTIA STAGE: A MULTI-STATE MODEL ANALYSIS 2017 , 13, P585-P586		4
475	Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015 , 1, 75-80	5.2	4
474	DT-01-02: Biomarker data from scarlet road: A global phase 3 study of gantenerumab in patients with prodromal Alzheimer's disease 2015 , 11, P331-P331		4
473	Biomarkers for Alzheimer's disease. Which way to go?. <i>Neurobiology of Aging</i> , 2004 , 25, 695-6	5.6	4
472	Retrograde amnesia for semantic information in Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2005 , 11, 40-8	3.1	4
471	Peripheral electrical stimulation in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005 , 19, 361-8	2.6	4
470	No evidence for abnormalities in kinetics of platelet monoamine oxidase in Alzheimer's disease. <i>Clinica Chimica Acta</i> , 1995 , 240, 99-102	6.2	4
469	SPECT, CT and MRI in a Turkish family with Huntington's disease. <i>Neuroradiology</i> , 1993 , 35, 525-8	3.2	4
468	Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 31	9	4
467	Profound regional spectral, connectivity, and network changes reflect visual deficits in posterior cortical atrophy: an EEG study. <i>Neurobiology of Aging</i> , 2020 , 96, 1-11	5.6	4

466	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimeris Disease</i> , 2020 , 77, 1353-1368	4.3	4
465	What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021 , 76, 1499-1511	4.6	4
464	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimeris and Dementia</i> , 2021 , 17, 1452-1464	1.2	4
463	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimeris and Dementia</i> , 2021 , 17, 1628-1640	1.2	4
462	Combinations of Service Use Types of People With Early Cognitive Disorders. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 620-5	5.9	4
461	Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , 2016 , 2, 233-240	6	4
460	Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019 , 73, 230.e9-230.e17	5.6	4
459	Kinetics and 28-day test-retest repeatability and reproducibility of [C]UCB-J PET brain imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021 , 41, 1338-1350	7.3	4
458	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. <i>Alzheimeris Research and Therapy</i> , 2021 , 13, 38	9	4
457	O3-09-06: A PROTOTYPE SIMOA ASSAY QUANTIFYING PLASMA AMYLOID BETA 1-42 AND 1-40 ISOFORMS CAN DIFFERENTIATE PARTICIPANTS WITH AD FROM HEALTHY CONTROL SUBJECTS 2018 , 14, P1039-P1039		4
456	The protective gene dose effect of the APOE ϵ allele on gray matter volume in cognitively unimpaired individuals. <i>Alzheimeris and Dementia</i> , 2021 ,	1.2	4
455	Using cerebrospinal fluid amyloid-beta(1-42) in the memory clinic: Concordance with PET and use of biomarker ratios across immunoassays. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045128	1.2	3
454	Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017 , 50, 77-86	5.6	3
453	[P2052]: THE DUTCH BRAIN HEALTH REGISTRY: OPTIMIZING RECRUITMENT FOR DEMENTIA RESEARCH 2017 , 13, P624-P624		3
452	Neurological signs in relation to white matter hyperintensity volumes in memory clinic patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010 , 29, 301-8	2.6	3
451	Tau and A β 42 protein in CSF of patients with frontotemporal degeneration. <i>Neurology</i> , 2003 , 60, 353-4; author reply 353-4	6.5	3
450	P2-201 Microglia activation in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2004 , 25, S286	5.6	3
449	Memantine in moderate-to-severe Alzheimer disease evidence and ethics based?. <i>Alzheimer Disease and Associated Disorders</i> , 2004 , 18, 47-8; author reply 48	2.5	3

448	Cerebrospinal fluid acetylcholinesterase homospecific activity in patients with "probable Alzheimer's disease". <i>Biological Psychiatry</i> , 1994 , 36, 708-9	7.9	3
447	(99mTc)-HM-PAO SPECT and dementia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992 , 55, 981	5.5	3
446	Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. <i>JMIR Research Protocols</i> , 2018 , 7, e80	2	3
445	Familial spastic paraplegia: evidence for a fourth locus. <i>Clinical Neurology and Neurosurgery</i> , 1997 , 99, 87-90	2	3
444	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. <i>Brain Communications</i> , 2020 , 2, fcaa177	4.5	3
443	Comorbid amyloid- β pathology affects clinical and imaging features in VCD. <i>Alzheimeris and Dementia</i> , 2020 , 16, 354-364	1.2	3
442	cCOG: A web-based cognitive test tool for detecting neurodegenerative disorders. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12083	5.2	3
441	Early life involvement in C9orf72 repeat expansion carriers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	3
440	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. <i>Biological Psychiatry</i> , 2021 , 89, 825-833	7.9	3
439	[F]Flortaucipir PET Across Various Mutations in Presymptomatic and Symptomatic Carriers. <i>Neurology</i> , 2021 , 97, e1017-e1030	6.5	3
438	White Matter Changes and Cognitive Decline in a Ten-Year Follow-Up Period: A Pilot Study on a Single-Center Cohort from the Leukoaraiosis and Disability Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016 , 41, 303-13	2.6	3
437	Circulating metabolites are associated with brain atrophy and white matter hyperintensities. <i>Alzheimeris and Dementia</i> , 2021 , 17, 205-214	1.2	3
436	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. <i>NeuroImage: Clinical</i> , 2021 , 30, 102660	5.3	3
435	Amyloid- β cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 348-358	5.3	3
434	Routine magnetoencephalography in memory clinic patients: A machine learning approach. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12227	5.2	3
433	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. <i>Journal of Alzheimeris Disease</i> , 2021 , 83, 269-279	4.3	3
432	Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12182	5.2	3
431	Clinico-Pathological Correlations of the Frontal Lobe Syndrome: Results of a Large Brain Bank Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015 , 40, 121-9	2.6	2

430	Interneuron hyperexcitability as both causal factor and risk factor in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e040877	1.2	2
429	Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. <i>Journal of Alzheimer's Disease</i> , 2018 , 65, 71-77	4.3	2
428	O4-11-04: ACTIVE ADJUVANT IMMUNOTHERAPY CAD106 PHASE II DOSE-ADJUVANT FINDING STUDY: SAFETY AND CNS BIOMARKERS 2014 , 10, P274-P274		2
427	[O3003]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY 2017 , 13, P924		2
426	IC-01-04: Diagnostic impact of [18F]flutemetamol amyloid imaging in young-onset dementia 2015 , 11, P3-P4		2
425	F2-03-04: Genetic risk factors for posterior cortical atrophy 2015 , 11, P168-P169		2
424	Using magnetic resonance imaging in diagnosing dementia: a Dutch outpatient memory clinics survey. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014 , 38, 281-5	2.6	2
423	An informant questionnaire for detecting Alzheimer's disease: are some items better than others?. <i>Journal of the International Neuropsychological Society</i> , 2011 , 17, 674-81	3.1	2
422	Emerging treatments in dementia. <i>European Neurology</i> , 1997 , 38, 184-9	2.1	2
421	Getting a grip on Alzheimer's disease: imaging amyloid in the brain. <i>Lancet Neurology</i> , 2007 , 6, 204-211	4.1	2
420	All patients with suspected dementia should be scanned at least once with CT or MRI. <i>International Psychogeriatrics</i> , 2007 , 19, 533-4; discussion 534-8	3.4	2
419	Targeting Lifestyle Behavior to Improve Brain Health: User-Experiences of an Online Program for Individuals with Subjective Cognitive Decline. <i>Journal of Prevention of Alzheimer's Disease</i> , 2020 , 7, 184-194	3.8	2
418	Effects of reference tissue versus plasma input parametric kinetic modelling on statistical parametric analysis of [11C](R)-PK11195 binding in Alzheimer's disease (AD) and young and old subjects. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005 , 25, S643-S643	7.3	2
417	Polygenic Risk Score of Longevity Predicts Longer Survival Across an Age Continuum. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021 , 76, 750-759	6.4	2
416	Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer's disease		2
415	Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020 , 33, 256-264	3.8	2
414	Hippocampal [F]flortaucipir BP corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. <i>NeuroImage: Clinical</i> , 2020 , 25, 102113	5.3	2
413	Cross-cultural adaptation and validation of the Amsterdam Instrumental Activities of Daily Living questionnaire short version German for Switzerland. <i>Health and Quality of Life Outcomes</i> , 2020 , 18, 323	3	2

412	End Stage Clinical Features and Cause of Death of Behavioral Variant Frontotemporal Dementia and Young-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 1169-1180	4.3	2
411	Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020 , 49, 2-7	2.6	2
410	Small vessel disease lesion type and brain atrophy: The role of co-occurring amyloid. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12060	5.2	2
409	The bvFTD phenocopy syndrome: a case study supported by repeated MRI, [F]FDG-PET and pathological assessment. <i>Neurocase</i> , 2021 , 27, 181-189	0.8	2
408	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. <i>Journal of Alzheimer's Disease</i> , 2021 , 82, 381-390	4.3	2
407	The plasma peptides of Alzheimer's disease. <i>Clinical Proteomics</i> , 2021 , 18, 17	5	2
406	Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow-up. <i>Brain and Behavior</i> , 2021 , 11, e2257	3.4	2
405	P4-224: Alzheimer's Disease Patients With Osas History Have Higher CSF Tau Levels 2016 , 12, P1115-P1115		2
404	O1-10-01: Gantenerumab Treatment Reduces Biomarkers of Neuronal and Synaptic Degeneration in Alzheimer's Disease 2016 , 12, P198-P198		2
403	F5-05-01: THE PAST, PRESENT, AND FUTURE OF INSTRUMENTAL ACTIVITIES OF DAILY LIVING ASSESSMENTS IN ALZHEIMER'S DISEASE 2016 , 12, P372-P373		2
402	Efficacy, Safety and Biomarker Data from SCarlet RoAD's Global Phase 3 Study of Gantenerumab in Patients with Prodromal AD. <i>American Journal of Geriatric Psychiatry</i> , 2016 , 24, S161-S162	6.5	2
401	CSF and amyloid pet biomarker data from scarlet road's a global Phase 3 study of gantenerumab in patients with prodromal AD. <i>Neurobiology of Aging</i> , 2016 , 39, S28-S29	5.6	2
400	Evaluating severity of white matter lesions from computed tomography images with convolutional neural network. <i>Neuroradiology</i> , 2020 , 62, 1257-1263	3.2	2
399	Risk of dementia in APOE4 carriers is mitigated by a polygenic risk score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12229	5.2	2
398	White matter microstructure disruption in early stage amyloid pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021 , 13, e12124	5.2	2
397	IC-P-192: DISEASE-STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE 2018 , 14, P158-P160		2
396	Right temporal variant frontotemporal dementia is pathologically heterogeneous: a case-series and a systematic review. <i>Acta Neuropathologica Communications</i> , 2021 , 9, 131	7.3	2
395	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021 , 9,	4.6	2

394	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. <i>Brain Communications</i> , 2021 , 3, fcab201	4.5	2
393	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCE project. <i>Neurobiology of Aging</i> , 2021 , 108, 146-154	5.6	2
392	Visual association encoding activates the medial temporal lobe: A functional magnetic resonance imaging study 1997 , 7, 594		2
391	Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer's disease.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 38	9	2
390	Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	2
389	Testing Episodic Memory in Elderly Subjects: Not as Simple as It Looks. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019 , 9, 207-216	2.5	1
388	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020 , 16, e036954	1.2	1
387	MEG detects abnormal hippocampal activity in amyloid-positive MCI. <i>Alzheimer's and Dementia</i> , 2020 , 16, e040796	1.2	1
386	Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041048	1.2	1
385	The evolution of neuropsychiatric symptoms in atypical variants of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045236	1.2	1
384	O5-07-02: Personalized Risk Estimates for MCI Patients: Taking Biomarkers Into the Clinic 2016 , 12, P393-P393		1
383	P1-258: CORTICAL PHASE CHANGES AT 7T MRI IN SUBJECTIVE COGNITIVE IMPAIRMENT AND THEIR ASSOCIATION WITH COGNITIVE FUNCTION 2014 , 10, P402-P402		1
382	P1-135: DIRECTED ANTERIOR-TO-POSTERIOR COMMUNICATION IN THE BRAIN IS REVERSED IN DEMENTIA WITH LEWY BODIES AND IS RELATED TO ATTENTION DEFICITS 2014 , 10, P349-P349		1
381	O4-01-05: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS 2014 , 10, P250-P250		1
380	O4-07-05: ADDED VALUE OF MRI BIOMARKERS TO NEUROPSYCHOLOGICAL TEST PERFORMANCE FOR PREDICTION OF AD IN SUBJECTS WITH MCI 2014 , 10, P265-P265		1
379	IC-P-109: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY: A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE 2014 , 10, P61-P61		1
378	P2-196: RESTING STATE CEREBRAL PERFUSION AND METABOLISM IN SUBJECTIVE MEMORY COMPLAINTS: ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA—TWO SIDES OF THE SAME COIN? 2014 , 10, P543-P543		1
377	O4-01-01: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA 2014 , 10, P248-P248		1

376	[P3886]: COMPUTED RATING SCALES FOR COGNITIVE DISORDERS FROM MRI 2017 , 13, P1108-P1108		1
375	[IC-P-005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID- β AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS 2017 , 13, P13-P14		1
374	[P2012]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER'S DISEASE (EMIF-AD): THE BIOMARKER DISCOVERY STUDY 2017 , 13, P691-P692		1
373	P4-089: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease 2015 , 11, P806-P807		1
372	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter Ip feasibility study 2015 , 11, P297-P297		1
371	F2-03-02: Early onset APOE-e4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains 2015 , 11, P168-P168		1
370	O3-14-04: The relation between eeg spectral analysis and clinical progression in non-demented, amyloid-positive subjects 2015 , 11, P255-P256		1
369	Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full?. <i>Alzheimer's Research and Therapy</i> , 2013 , 5, 26	9	1
368	Nutrition and dementia. <i>European Journal of Neurology</i> , 2009 , 16 Suppl 1, iii-iv	6	1
367	Feature extraction and strategy of analyzing structural neuroimaging in dementia. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2008 , 89, 75-86	3	1
366	Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 1039	5.5	1
365	Neuroimaging in old age psychiatry. <i>Current Opinion in Psychiatry</i> , 2004 , 17, 449-452	4.9	1
364	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022 , 1	8.8	1
363	Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's disease 2020 ,		1
362	Data-driven approaches for Tau-PET imaging biomarkers in Alzheimer's disease		1
361	Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease (Preprint)		1
360	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset		1
359	A Semi-supervised Large Margin Algorithm for White Matter Hyperintensity Segmentation. <i>Lecture Notes in Computer Science</i> , 2016 , 104-112	0.9	1

358	Disorders Mainly Affecting White Matter 2011 , 177-242		1
357	Magnetic Resonance and Dementia 2002 , 1-4		1
356			
355	Amyloid- β /CSF/PET discordance vs tau load 5 years later: It takes two to tangle		1
354	Contribution of genetic and environmental factors to the onset of preclinical Alzheimer's disease - a monozygotic twin study		1
353	Exome sequencing identifies rare damaging variants in the ATP8B4 and ABCA1 genes as novel risk factors for Alzheimer's Disease		1
352	Neuropathology and cognitive performance in centenarians		1
351	Data-driven detection of latent atrophy factors related to phenotypical variants of posterior cortical atrophy		1
350	MicroRNA Analysis in the Spinal Fluid of Alzheimer Patients: A Methodological Feasibility Study 2010 , 275-282		1
349	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020 , 10, 12184	4.9	1
348	Prediction of poor clinical outcome in vascular cognitive impairment: TRACE-VCI study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12077	5.2	1
347	The natural history of primary progressive aphasia: beyond aphasia. <i>Journal of Neurology</i> , 2021 , 1	5.5	1
346	P4-153: Subjective Cognitive Decline and Progression to Dementia Due to AD and Non-AD in Memory Clinic and Community-Based Cohorts 2016 , 12, P1073-P1073		1
345	IC-P-182: EVENT-BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL β AMYLOID DEPOSITION IN THE BRAIN 2018 , 14, P152-P152		1
344	IC-P-092: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY 2018 , 14, P76-P79		1
343	P4-106: DECLINE IN GREY MATTER CONNECTIVITY OVER TIME IS RELATED TO CLINICAL PROGRESSION IN MCI DUE TO AD 2018 , 14, P1479-P1479		1
342	P2-445: EVENT-BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL β AMYLOID DEPOSITION IN THE BRAIN 2018 , 14, P887-P888		1
341	P1-602: DUTCH ONLINE REGISTRY FOR RECRUITMENT OF PARTICIPANTS FOR DEMENTIA STUDIES: HERSENONDERZOEK.NL AND BRAIN HEALTH REGISTRY 2018 , 14, P569-P570		1

340	Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD. <i>Alzheimeris Research and Therapy</i> , 2021 , 13, 142	9	1
339	Responding to responsive behaviour in Alzheimer's disease - Author's reply. <i>Lancet, The</i> , 2021 , 398, 842	40	1
338	Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis?. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , 2021 , 7, e12189	6	1
337	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.. <i>Molecular Neurodegeneration</i> , 2022 , 17, 27	19	1
336	The Effect of Alzheimer's Disease-Associated Genetic Variants on Longevity.. <i>Frontiers in Genetics</i> , 2021 , 12, 748781	4.5	1
335	Cerebrospinal fluid proteomic profiles predict progression to dementia in prodromal AD. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045230	1.2	0
334	A mixed-methods approach to establish clinically meaningful categories of impairment in instrumental activities of daily living. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045693	1.2	0
333	Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045829	1.2	0
332	Pre-trained MRI-based Alzheimer's disease classification models to classify memory clinic patients. <i>NeuroImage: Clinical</i> , 2020 , 27, 102303	5.3	0
331	Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , 2020 , 21, 1436-1438	5.9	0
330	IC-P-076: WHITE MATTER HYPERINTENSITIES PREDICT MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN PATIENTS WITH SUBJECTIVE COGNITIVE COMPLAINTS 2014 , 10, P42-P43		0
329	P3-096: MAGNETOENCEPHALOGRAPHY IN DEMENTIA: THE STATE OF THE ART 2014 , 10, P663-P663		0
328	Ondersteuning bij visuele problemen in het kader van posterieure corticale atrofie Een casus. <i>Neuropraxis</i> , 2017 , 21, 4-10	0	0
327	Can lumbar puncture help to identify patients with incipient Alzheimer's disease?. <i>Nature Clinical Practice Neurology</i> , 2006 , 2, 530-1		0
326	Everyday Functioning in a Community-Based Volunteer Population: Differences Between Participant- and Study Partner-Report.. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 761932	5.3	0
325	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline.. <i>Brain Communications</i> , 2022 , 4, fcac026	4.5	0
324	An Operational Definition of 'Abnormal Cognition' to Optimize the Prediction of Progression to Dementia: What Are Optimal Cut-Off Points for Univariate and Multivariate Normative Comparisons?. <i>Journal of Alzheimeris Disease</i> , 2020 , 77, 1693-1703	4.3	0
323	Patients to learn from: on the need for systematic integration of research and care in academic health care. <i>Journal of Clinical and Translational Research</i> , 2018 , 3, 401-406	1.1	0

322	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12120	5.2	0
321	The predictive value of normal EEGs in dementia due to Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1038-1048	5.3	0
320	IC-P-153: Thinner Cortical Thickness in Patients With Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function 2016 , 12, P113-P114		0
319	Sociale cognitie bij frontotemporale dementie. <i>Neuropraxis</i> , 2019 , 23, 120-125	0	0
318	Biomarker testing in MCI patients-deciding who to test. <i>Alzheimeris Research and Therapy</i> , 2021 , 13, 14	9	0
317	Commentary: Aducanumab: Appropriate Use Recommendations. <i>Journal of prevention of Alzheimeris disease, The</i> , 2021 , 8, 412-413	3.8	0
316	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. <i>Translational Psychiatry</i> , 2021 , 11, 451	8.6	0
315	Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups. <i>NeuroImage: Clinical</i> , 2021 , 31, 102725	5.3	0
314	Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022 , 3, 100141	0	0
313	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 840651	5.3	0
312	From corticocentrism to leucocentrism or both. <i>Brain</i> , 2017 , 140, 247-250	11.2	
311	[IC-P-130]: MRI-BASED CLASSIFICATION ACCURACY OF DEMENTIA TYPE IS DETERMINED BY MRI MODALITY 2017 , 13, P98-P99		
310	[P1B92]: AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA 2017 , 13, P417-P418		
309	Amyloid-β/CSF/PET discordance vs tau load 5 years later: It takes two to tangle. <i>Alzheimeris and Dementia</i> , 2020 , 16, e037246	1.2	
308	Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. <i>Alzheimeris and Dementia</i> , 2020 , 16, e037912	1.2	
307	Relationship between clinical symptomatology and disease burden in dementia with Lewy bodies: An overview of the DEVELOP baseline results. <i>Alzheimeris and Dementia</i> , 2020 , 16, e039306	1.2	
306	Associations of nutritional parameters with clinical progression in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer's disease: The NUDAD project. <i>Alzheimeris and Dementia</i> , 2020 , 16, e039848	1.2	
305	Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. <i>Alzheimeris and Dementia</i> , 2020 , 16, e040152	1.2	

- 304 Neuronal network hyperactivity in computational models of AD. *Alzheimeris and Dementia*, **2020**, 16, e040407 1.2
- 303 Impact of the disclosure of amyloid-PET results to patients with subjective cognitive decline: the AMYPAD Diagnostic and Patient Management Study (DPMS). *Alzheimeris and Dementia*, **2020**, 16, e040952^{1,2}
- 302 Early-onset Alzheimer's disease is related to differential spatial patterns of tau pathology and cognitive impairment. *Alzheimeris and Dementia*, **2020**, 16, e042041 1.2
- 301 Beyond aphasia: Natural history of the aphasia onset dementia syndromes. *Alzheimeris and Dementia*, **2020**, 16, e042105 1.2
- 300 Polygenic risk score for Alzheimer's disease is related to amyloid positivity in subjective cognitive decline: The SCIENCe project. *Alzheimeris and Dementia*, **2020**, 16, e042116 1.2
- 299 Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: The NUDAD project. *Alzheimeris and Dementia*, **2020**, 16, e042429 1.2
- 298 Pronounced regional spectral, connectivity and network changes reflect visual deficits in posterior cortical atrophy: An EEG study on PCA. *Alzheimeris and Dementia*, **2020**, 16, e042561 1.2
- 297 Immune response and endocytosis pathways are associated with the resilience against Alzheimer's disease. *Alzheimeris and Dementia*, **2020**, 16, e042614 1.2
- 296 Differential diagnosis of dementia combining web-based cognitive testing and MRI. *Alzheimeris and Dementia*, **2020**, 16, e042626 1.2
- 295 Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants. *Alzheimeris and Dementia*, **2020**, 16, e042628 1.2
- 294 Examining centiloid quantification against visual assessment using [18F]flutemetamol PET. *Alzheimeris and Dementia*, **2020**, 16, e042653 1.2
- 293 Computerized decision support to select memory clinic patients for amyloid PET: Which patient to test?. *Alzheimeris and Dementia*, **2020**, 16, e042687 1.2
- 292 BDNF-Met polymorphism on top of amyloid pathology predisposes for faster cognitive decline in cognitively normal elderly: The SCIENCe Project. *Alzheimeris and Dementia*, **2020**, 16, e042728 1.2
- 291 Biomarker testing in MCI patients: Deciding who to tap. *Alzheimeris and Dementia*, **2020**, 16, e042735 1.2
- 290 Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. *Alzheimeris and Dementia*, **2020**, 16, e042739^{1,2}
- 289 A loss of neuronal inhibition best explains EEG abnormalities in preclinical Alzheimer's disease: A multiscale computational modeling study. *Alzheimeris and Dementia*, **2020**, 16, e043262 1.2
- 288 Current status and quantitative results of the AMYPAD prognostic and natural history study. *Alzheimeris and Dementia*, **2020**, 16, e044711 1.2
- 287 Dutch Brain Research Registry for online study participant recruitment: Design and first results. *Alzheimeris and Dementia*, **2020**, 16, e044738 1.2

286	An RCT to identify best practices for disclosure of amyloid imaging results in mild cognitive impairment: The ABIDE simulation study. <i>Alzheimeris and Dementia</i> , 2020 , 16, e044761	1.2
285	Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: The SCIENCE project. <i>Alzheimeris and Dementia</i> , 2020 , 16, e044783	1.2
284	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. <i>Alzheimeris and Dementia</i> , 2020 , 16, e044787	1.2
283	Heterogeneous distribution of pathology in behavioral variant Alzheimer's disease. <i>Alzheimeris and Dementia</i> , 2020 , 16, e044830	1.2
282	Amyloid aggregation and subsequent memory decline over time in cognitively intact older identical twins. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045112	1.2
281	Serum neurofilament light in memory clinic practice. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045155	1.2
280	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non-demented memory clinic participants. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045196	1.2
279	Grey zone amyloid burden heralds future memory decline: The SCIENCE Project. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045210	1.2
278	Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045470	1.2
277	Plasma amyloid- β oligomerization assay as a screening test for abnormal amyloid status. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045754	1.2
276	Assessment of cortical vulnerability of the anterior cingulate cortex in the behavioral variant of Alzheimer's disease. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045770	1.2
275	Regional tau pathology is associated with loss of synapses and reduced synaptic activity: A combined [18F]flortaucipir, [11C]UCB-J and magnetoencephalography study. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045806	1.2
274	DNA methylation differences associated with peripheral biomarkers in the EMIF-AD cohort. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045853	1.2
273	Regional distribution of tau pathology in cognitively unimpaired, genetically identical twins. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045876	1.2
272	Increased 18F-flortaucipir load correlates with changes in MEG functional connectivity and network topology, as well as oscillatory slowing. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045911	1.2
271	Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. <i>Alzheimeris and Dementia</i> , 2020 , 16, e046102	1.2
270	S4-01-01: Cross-Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau 2016 , 12, P321-P321	
269	O4-09-05: Risk Factors for Cognitive Decline are Age Dependent 2016 , 12, P356-P356	

- 268 IC-P-011: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients **2016**, 12, P19-P20
- 267 P2-342: Thinner Cortical Thickness in Patients with Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function **2016**, 12, P774-P774
- 266 Cerebrospinal Fluid Amyloid- β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study. *Journal of Alzheimer's Disease*, **2019**, 71, 15-20 4-3
- 265 O2-13-05: APOLIPOPROTEIN A-1 IS ASSOCIATED WITH DECLINE IN PRECLINICAL AD **2014**, 10, P195-P196
- 264 O5-02-02: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY **2014**, 10, P291-P292
- 263 O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA **2014**, 10, P194-P195
- 262 P3-031: AMYLOID-BETA DEGRADATION BY HUMAN ASTROCYTES IS IMPAIRED BY APOJ AND APOE **2014**, 10, P638-P638
- 261 P1-223: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE **2014**, 10, P385-P386
- 260 O4-06-02: CSF AD-PROFILE IN DEMENTIA WITH LEWY BODIES: EFFECT ON CLINICAL PARAMETERS AND COGNITIVE DECLINE **2014**, 10, P261-P262
- 259 IC-P-085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE **2014**, 10, P48-P49
- 258 O2-08-06: THE FUTURE OF CARE: THE DIGITAL ALZHEIMER CENTER EVALUATION OF AN ONLINE PORTAL FOR PATIENTS WITH DEMENTIA AND THEIR INFORMAL CAREGIVERS **2014**, 10, P181-P182
- 257 P1-015: PROTEIN KINASE ACTIVITY DECREASES WITH BRAAK STAGE IN HIPPOCAMPAL POSTMORTEM BRAIN TISSUE AS REVEALED BY USING A PEPTIDE-BASED MICROARRAY PLATFORM **2014**, 10, P309-P309
- 256 P1-385: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY, A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF A NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER'S DISEASE **2014**, 10, P455-P456
- 255 O2-07-04: COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS **2014**, 10, P178-P179
- 254 P1-381: EFFECTS OF THE MEDICAL FOOD SOUVENOID ON PLASMA NUTRIENT LEVELS IN MILD ALZHEIMER'S DISEASE DURING 48 WEEKS **2014**, 10, P454-P454
- 253 O5-05-04: MATRIX METALLOPROTEINASES IN RELATION TO ALZHEIMER'S DISEASE AND CAA **2014**, 10, P300-P300
- 252 IC-P-057: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POST MORTEM CONFIRMED DEMENTIAS **2014**, 10, P32-P33
- 251 IC-P-077: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY **2014**, 10, P43-P44

250 P3-403: CAPTURING CHANGES IN EVERYDAY FUNCTIONING **2014**, 10, P778-P778

249 O4-01-06: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN **2014**, 10, P250-P251

248 O1-09-06: A EUROPEAN BIOBANK FOR THE VALIDATION OF NEW MARKERS FOR ALZHEIMER'S AND PARKINSON'S DISEASE: THE BIOMARKAPD PROJECT **2014**, 10, P148-P148

247 O2-14-03: THE REST-ACTIVITY RHYTHM IS RELATED TO THE LEVEL OF PHYSICAL ACTIVITY IN EARLY-ONSET DEMENTIA **2014**, 10, P197-P198

246 IC-P-056: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE **2014**, 10, P31-P32

245 P1-134: LOSS OF NETWORK INTEGRATION IS RELATED TO COGNITIVE IMPAIRMENT IN DEMENTIA WITH LEWY BODIES **2014**, 10, P349-P349

244 P1-149: CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE **2014**, 10, P355-P355

243 P1-233: MULTIMODAL BRAIN NETWORK ALTERATIONS IN ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT PATIENTS **2014**, 10, P389-P390

242 P4-273: CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE **2014**, 10, P884-P884

241 O1-02-04: 7T T2*-WEIGHTED MRI REVEALS CORTICAL PHASE DIFFERENCES BETWEEN EARLY- AND LATE-ONSET AD **2014**, 10, P132-P133

240 O2-08-05: THE DIGITAL ALZHEIMER CENTER: A NEXT STEP TOWARD INNOVATIVE DEMENTIA CARE **2014**, 10, P181-P181

239 O2-13-01: PREVALENCE AND PROGNOSIS OF PRODROMAL ALZHEIMER'S DISEASE: A COMPARISON OF THE INTERNATIONAL WORKING GROUP CRITERIA AND NATIONAL INSTITUTE OF AGING-ALZHEIMER'S ASSOCIATION CRITERIA **2014**, 10, P193-P193

238 P1-174: CEREBROVASCULAR DISEASE IN LATE ONSET FRONTAL LOBE SYNDROME **2014**, 10, P363-P363

237 P1-415: STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT **2014**, 10, P465-P466

236 P2-190: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POSTMORTEM CONFIRMED DEMENTIAS **2014**, 10, P540-P541

235 P4-351: A PLASMA PHOSPHOLIPID BIOMARKER PROFILE FOR DETECTING PRECLINICAL ALZHEIMER'S DISEASE CAN BE MODIFIED BY ORAL INTAKE OF NUTRIENTS THAT INCREASE PHOSPHOLIPID SYNTHESIS **2014**, 10, P916-P917

234 IC-P-115: Longitudinal white matter alterations of MCI patients in WP5 PharmaCog/E-ADNI study: Preliminary data **2015**, 11, P79-P79

233 P3-158: Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly **2015**, 11, P689-P689

232 P4-040: Use of recent research criteria for inclusion and use of biomarkers as endpoint in preclinical and prodromal Alzheimer's disease (AD) trials: An Alzheimer's disease neuroimaging initiative (ADNI) study **2015**, 11, P780-P781

231 P1-174: Diagnostic impact of [¹⁸F]flutemetamol amyloid imaging in young onset dementia **2015**, 11, P411-P412

230 P3-072: Are relations between ApoE genotype and ad-related pathology in nondemented elderly mediated by CSF apolipoproteins? **2015**, 11, P644-P644

229 O4-05-04: A four-center study on the effect of polygenic risk score on cerebrospinal fluid markers and memory decline in mild cognitive impairment patients **2015**, 11, P279-P279

228 IC-P-116: Hippocampal subfield changes in mild cognitive impairment patients with Alzheimer's disease pathology **2015**, 11, P79-P80

227 IC-04-05: Multisite hippocampal subfields reproducibility: A european 3T study **2015**, 11, P12-P12

226 IC-P-124: Classification of resting-state cerebral perfusion maps from patients with Alzheimer's disease and patients with frontotemporal dementia **2015**, 11, P85-P85

225 P4-088: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease **2015**, 11, P806-P806

224 P1-093: Dementia and rapid mortality: Who's at risk? **2015**, 11, P374-P374

223 P2-298: Altered plasma and CSF levels of nutrients that enhance neuronal phospholipid synthesis in Alzheimer's disease: A retrospective cohort study **2015**, 11, P606-P607

222 Frontotemporale dementie en de psychiatrische differentiaaldiagnose: twee gevalsbeschrijvingen en de rationale van de Laat Ontstaan Frontaal syndroom (LOF)-studie *Tijdschrift Voor Neuropsychiatrie En Gedragsneurologie*, **2013**, 1, 72-79

221 Familiegesprekken voor mantelzorgers van mensen met dementie. *Huisarts En Wetenschap*, **2013**, 56, 160-164 0.1

220 S10202: Clinical and neuropsychological features as predictors from MCI to Alzheimer's-type dementia **2013**, 9, P122-P122

219 O30501: Physical activity, independent functioning and emotional well-being in early-onset dementia **2013**, 9, P526-P526

218 O10901: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting **2013**, 9, P144-P145

217 [P2045]: AMYLOID VISUALIZATION IN THE RETINA OF ALZHEIMER'S DISEASE PATIENTS WITH CURCUMIN **2017**, 13, P705-P706

216 [P1044]: DISCRIMINATION BETWEEN DEMENTIA WITH LEWY BODIES (DLB), ALZHEIMER'S DISEASE (AD) AND MIXED PATHOLOGY USING ELECTRO-ENCEPHALOGRAPHY (EEG) **2017**, 13, P338-P339

215 [P2099]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P783-P783

- 214 [P2873]: THE EFFECTS OF AMYLOID ON SEMANTIC COMPLEXITY IN SPONTANEOUS SPEECH IN SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P821-P822
- 213 [P3161]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL A β CLEARANCE? **2017**, 13, P995-P996
- 212 [P3026]: PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER'S DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES **2017**, 13, P1024-P1025
- 211 [P3875]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT **2017**, 13, P1102-P1103
- 210 [P3807]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER'S DISEASE **2017**, 13, P1120-P1121
- 209 [P3822]: CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA **2017**, 13, P1127-P1128
- 208 [P3827]: NON-AMNESTIC ALZHEIMER'S DISEASE: A POSSIBLE ROLE FOR NEUROINFLAMMATION? **2017**, 13, P1131-P1131
- 207 [P4019]: [18F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P1352-P1353
- 206 [P4035]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPIR **2017**, 13, P1364-P1364
- 205 [P4802]: DOES BRAIN AMYLOID DEPOSITION IMPACT EVERYDAY FUNCTIONING IN SUBJECTS WITH COGNITIVE COMPLAINTS? RESULTS FROM THE INSIGHT COHORT **2017**, 13, P1406-P1406
- 204 [IC-P-036]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P32-P32
- 203 [IC-P-037]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER'S DISEASE **2017**, 13, P33-P34
- 202 [IC-P-053]: EARLY ALTERATIONS IN RESTING-STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS **2017**, 13, P43-P44
- 201 [IC-P-055]: EFFECT OF APOE- ϵ ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE **2017**, 13, P45-P46
- 200 [IC-P-058]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P47-P48
- 199 [IC-P-065]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P53-P54
- 198 [IC-P-085]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT **2017**, 13, P69-P69
- 197 [IC-P-095]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE **2017**, 13, P74-P75

- 196 [IC-P-106]: PREDICTING PROGRESSION IN PRE-DEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE **2017**, 13, P81-P82
- 195 [IC-P-110]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P87-P87
- 194 [IC-P-203]: [18F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P148-P149
- 193 [IC-P-206]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPIR **2017**, 13, P150
- 192 [P1050]: DECISION TREE ANALYSIS REVEALS TWO CUT-OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS **2017**, 13, P342-P343
- 191 [P1076]: BRI2 DEMENTIA PATHWAY IN CSF, IMPROVING DETECTION THROUGH ULTRASENSITIVE SIMOA TECHNOLOGY **2017**, 13, P355-P355
- 190 [P1083]: RETINAL THICKNESS CORRELATES WITH PARIETAL CORTICAL ATROPHY ON MRI **2017**, 13, P359-P359
- 189 [P1089]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF A β OR AMYLOID-PET) IN THE EMIF-AD BIOMARKER DISCOVERY COHORT **2017**, 13, P361-P362
- 188 [P1087]: CHARACTERIZATION OF SUSPECTED NON-ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT USING NEUROIMAGING **2017**, 13, P414-P414
- 187 [P1004]: EARLY ALTERATIONS IN RESTING-STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS **2017**, 13, P429-P429
- 186 [P1011]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P433-P434
- 185 [P1040]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P451-P451
- 184 [P2007]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID- β AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS **2017**, 13, P688-P688
- 183 [P2035]: EFFECT OF APOE ϵ ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE **2017**, 13, P748-P750
- 182 [F10304]: BIOMARKER-BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P177
- 181 [PL-01001]: BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE **2017**, 13, P180
- 180 [O10102]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE **2017**, 13, P182
- 179 [O10503]: CSF AMYLOID BETA β 2 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSIS-DEPENDENT UPWARD DRIFT **2017**, 13, P198-P199

- 178 [O20101]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE) **2017**, 13, P547-P548
- 177 [O20501]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P559-P560
- 176 [O20006]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM **2017**, 13, P579
- 175 [O20103]: PREDICTING PROGRESSION IN PRE-DEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE **2017**, 13, P581-P582
- 174 [O30604]: PROMINENT NON-MEMORY DEFICITS IN AD ARE ASSOCIATED WITH A FASTER DISEASE PROGRESSION **2017**, 13, P912
- 173 [O50704]: COGNITIVE PERFORMANCE AND ALZHEIMER-ASSOCIATED PATHOLOGY IN THE CONTEXT OF EXTREME AGING **2017**, 13, P1472
- 172 [DT-0102]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT **2017**, 13, P1474-P1475
- 171 [P2094]: USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NON-ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT **2017**, 13, P680-P681
- 170 [P3075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS **2017**, 13, P960-P961
- 169 P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease **2015**, 11, P414-P414
- 168 IC-P-079: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease **2015**, 11, P57-P57
- 167 O4-10-02: Cross-cultural differences in instrumental activities of daily living (IADL): Translations and adaptations of the amsterdam iadl questionnaire **2015**, 11, P293-P293
- 166 IC-04-03: Grey matter network disruptions are related to amyloid-beta in cognitively healthy elderly **2015**, 11, P11-P11
- 165 IC-P-092: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning **2015**, 11, P64-P64
- 164 P3-182: Hippocampal subfield changes in mild cognitive impairment patients with Alzheimer's disease pathology **2015**, 11, P700-P701
- 163 IC-P-062: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease **2015**, 11, P46-P47
- 162 O3-09-02: An eeg study into functional connectivity and hubs in Alzheimer's disease: What's going on in the posterior regions? **2015**, 11, P237-P238
- 161 P2-174: Multi-site hippocampal subfields reproducibility: A european 3T study **2015**, 11, P558-P558

- 160 P4-242: A case-control cohort study to define a threshold for the tau/abeta42 ratio in cerebrospinal fluid optimized for diagnosis of Alzheimer's disease **2015**, 11, P873-P873
- 159 O2-02-06: Slow gait speed and low grip strength are related to worse attention and mental speed in patients with subjective cognitive decline and mild cognitive impairment **2015**, 11, P177-P177
- 158 F2-03-03: Characterization of the behavioral and dysexecutive variants of Alzheimer's disease **2015**, 11, P168-P168
- 157 P3-142: Alzheimer's biomarkers in daily practice (ABIDE): Study design **2015**, 11, P679-P680
- 156 IC-P-093: Distinct patterns of atrophy in postmortem confirmed dementias **2015**, 11, P64-P65
- 155 P4-087: Longitudinal white matter alterations of MCI patients in WP5 PharmaCog/E-ADNI study: Preliminary data **2015**, 11, P805-P806
- 154 O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset **2015**, 11, P140-P142
- 153 O3-11-02: Prevalence and diagnostic procedures in early-onset dementia in tertiary referral center patients in denmark, sweden, and the netherlands **2015**, 11, P244-P245
- 152 O3-14-02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool **2015**, 11, P254-P255
- 151 F4-02-02: The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors **2015**, 11, P260-P261
- 150 FTS-04-01: Diagnostic impact of biomarkers including CSF and PET in a tertiary memory clinic **2015**, 11, P263-P263
- 149 O4-08-05: Distinct patterns of atrophy in postmortem-confirmed dementias **2015**, 11, P288-P289
- 148 O4-08-06: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning **2015**, 11, P289-P289
- 147 O5-02-03: Reduced cortical thickness in patients with subjective cognitive decline is related to clinical progression **2015**, 11, P317-P317
- 146 O5-05-03: Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease **2015**, 11, P326-P326
- 145 THE COMBINATION OF HIPPOCAMPAL ATROPHY ON MRI AND CSF IS A BIOMARKER FOR FRONTOTEMPORAL DEMENTIA IN EARLY ONSET DEMENTIA **2014**, 10, P287-P288
- 144 O3-06-02: A RE-EVALUATION OF EARLY ALZHEIMER'S DISEASE BIOMARKERS ACCOUNTING FOR INACCURACY OF THE CLINICAL DIAGNOSIS **2014**, 10, P219-P219
- 143 S2-02-01: Understanding (endo)phenotypical heterogeneity: The role of age and APOE **2012**, 8, P228-P228

142 O4-03-01: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease **2012**, 8, P618-P618

141 Leeftijd: een belangrijke factor voor cognitieve profielen van de ziekte van Alzheimer. *Neuropraxis*, **2012**, 16, 183-191 0

140 Man with subjective complaints but abnormal CSF13-17

139 Inflammatory markers in AD and MCI patients with different biomarker profiles Interpretation of serum and CSF levels. *Neurobiology of Aging*, **2010**, 31, 1655 5.6

138 F3-01-01: The development of a new IADL informant-based questionnaire: The Amsterdam IADL questionnaire **2010**, 6, S115-S116

137 Lessons Learned in Eastern Europe **2012**, 99-103

136 Depressie en angst bij partners van dementiepatiënten. *Huisarts En Wetenschap*, **2010**, 53, 420-424 0.1

135 De huidige medicamenteuze behandeling van de ziekte van Alzheimer. *Neuropraxis*, **1998**, 2, 117-120 0

134 Simon B. N. Thompson, *Dementia and Memory: A Handbook for Students and Professionals*, Ashgate, Aldershot, Hampshire, 2006, 256 pp., hbk £50.00, ISBN 13: 978 0 7546 4633 4.. *Ageing and Society*, **2008**, 28, 137-138 1.7

133 De diagnostische waarde van de Visuele Associatie Test (vat) in een geheugenpoliklinieksetting. *Neuropraxis*, **2008**, 12, 3-8 0

132 Chapter 15 Advances in Neuroimaging. *Blue Books of Neurology*, **2007**, 30, 381-410

131 A 24-year follow-up of body mass index and cerebral atrophy. *Neurology*, **2005**, 64, 1990-1; author reply 1990-1 6.5

130 Validation and test-retest repeatability performance of parametric methods for [C]UCB-J PET.. *EJNMMI Research*, **2022**, 12, 3 3.6

129 The Impact of Amyloid PET Disclosure on Quality of Life in Patients With Young Onset Dementia.. *Alzheimer Disease and Associated Disorders*, **2022**, 36, 1-6 2.5

128 Magnetic Resonance: Applications in Dementia **2002**, 5-25

127 Neurodegenerative Disorders **2002**, 31-138

126 Diagnostiek en classificatie van dementie **2018**, 15-29

125 White matter integrity disruption in early amyloid accumulators. *Alzheimeris and Dementia*, **2020**, 16, e043021 1.2

- 124 Clinical Evaluation and Treatment of Cognitive Dysfunction and Dementia **2009**, 103-127
- 123 Dementia: Clinical Background **2011**, 5-11
- 122 Dementias with Associated Brain Swelling **2011**, 243-268
- 121 Primary Grey Matter Loss **2011**, 59-135
- 120 The Toolbox **2011**, 13-42
- 119 Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings **2014**, 185-211
- 118 Cerebrospinalfluid biomarkers of frontotemporal lobar degeneration **2014**, 143-152
- 117 P1-297: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients **2016**, 12, P534-P535
- 116 P2-221: Cerebral Blood Flow Measured with Phase-Contrast MRI in AD, MCI and Controls **2016**, 12, P706-P706
- 115 P4-122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline **2016**, 12, P1059-P1061
- 114 IC-P-196: Quantification of TAU Load Using [18F]AV-1451 and PET **2016**, 12, P141-P142
- 113 P1-178: Impact of Co-Morbid Amyloid Pathology on Clinical Phenotype of Patients with Vascular Cognitive Disorders **2016**, 12, P472-P472
- 112 IC-P-017: Concordance of [18F]Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs **2016**, 12, P23-P23
- 111 IC-02-04: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs **2016**, 12, P7-P8
- 110 IC-03-05: EEG Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer's Disease And Controls **2016**, 12, P12-P12
- 109 P1-298: The Influence of Concomitant Alzheimer Pathology on Atrophy in Dementia with Lewy Bodies (DLB): A Comparative MRI Study **2016**, 12, P535-P535
- 108 P1-339: Different Pathological Distribution Pattern of Phosphorylated TAU and Microglia in Amnestic and Non-Amnestic Alzheimer's Disease **2016**, 12, P558-P559
- 107 P2-015: Pooled Amyloid Pet Baseline Data from The Bapineuzumab IV Phase III Trials **2016**, 12, P614-P615

- 106 IC-P-097: A Novel Neuroimaging Approach to Capture Cognitive Reserve **2016**, 12, P74-P75
- 105 IC-P-103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer's Disease **2016**, 12, P78-P79
- 104 P2-165: Resilience to Clinical Dementia at Old Age: The European Medical Information Framework (EMIF) 90+ Study **2016**, 12, P678-P678
- 103 IC-P-108: Cerebral Blood Flow Measured With Phase-Contrast MRI in AD, MCI and Controls **2016**, 12, P82-P82
- 102 P2-237: Concordance of [18F]Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs **2016**, 12, P714-P715
- 101 P2-282: EEG-Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer's Disease and Controls **2016**, 12, P738-P738
- 100 P2-300: Capturing Changes in Cognition: The Needs and Wishes of Dementia Researchers and Clinicians **2016**, 12, P748-P748
- 99 IC-P-147: Atrophy Patterns Predicting Cognitive Decline in Non-Demented Subjects are Independent of Amyloid Pathology **2016**, 12, P109-P110
- 98 P3-144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts **2016**, 12, P873-P874
- 97 P3-269: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs **2016**, 12, P935-P936
- 96 P4-112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Non-Demented Elderly **2016**, 12, P1055-P1056
- 95 P4-146: Large-Vessel Disease and [18F]Flutemetamol-Amyloid Deposition in Cognitively Healthy Elderly Twins **2016**, 12, P1069-P1070
- 94 P4-191: A Novel Neuroimaging Approach to Capture Cognitive Reserve **2016**, 12, P1095-P1096
- 93 P4-215: Quantification of Tau Load Using [18F]AV-1451 and Pet **2016**, 12, P1109-P1110
- 92 FTS3-01-03: Biomarkers for Vascular Contributions to Dementia **2016**, 12, P276-P277
- 91 O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer's Disease **2016**, 12, P169-P170
- 90 FTS2-01-04: The Dutch Dementia Delta Plan (DDDP) **2016**, 12, P220-P220
- 89 O4-02-04: Atrophy Patterns Predicting Cognitive Decline in Non-Demented Subjects are Independent of Amyloid Pathology **2016**, 12, P335-P336

- 88 P1-238: When Less is More: Detecting Functional Decline Using a Short Version of the Amsterdam IADL Questionnaire **2016**, 12, P498-P499
- 87 IC-P-100: A LONGITUDINAL STUDY OF THE EFFECTS OF EDUCATION AND INTRACRANIAL VOLUME ON COGNITIVE CHANGES AND MORTALITY RATES IN ALZHEIMER'S DISEASE **2019**, 15, P87-P87
- 86 P4-525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE **2019**, 15, P1515-P1516
- 85 F2-01-01: NEURODEVELOPMENTAL DIFFERENCES AND ENVIRONMENTAL INSULTS INVERSELY CORRELATE WITH AGE OF ONSET IN ALZHEIMER'S DISEASE **2019**, 15, P515-P516
- 84 IC-P-025: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE **2019**, 15, P32-P33
- 83 IC-02-01: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE **2019**, 15, P1-P1
- 82 IC-P-076: FDG-PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELY-DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE **2019**, 15, P68-P70
- 81 IC-P-015: VOXEL-BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE CONTINUUM **2019**, 15, P24-P25
- 80 IC-P-097: DIFFERENTIATING THE BEHAVIOURAL VARIANT OF ALZHEIMER'S DISEASE FROM BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA AND TYPICAL ALZHEIMER'S DISEASE: THE VALUE OF NEUROIMAGING **2019**, 15, P84-P85
- 79 Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [F]Flortaucipir and [F]Florbetapir Brain PET Studies. *Molecular Imaging and Biology*, **2021**, 23, 550-559 3.8
- 78 P3-403: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE **2018**, 14, P1257-P1257
- 77 O3-13-01: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE **2018**, 14, P1054-P1055
- 76 P1-476: CORTICAL T1-W/T2-W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS **2018**, 14, P506-P507
- 75 O1-14-04: IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESION-SYMPTOM MAPPING STUDY **2018**, 14, P259-P259
- 74 P2-470: DIFFERENT CO-LOCALIZATION OF NEUROINFLAMMATORY MARKERS IN PLAQUES OF ATYPICAL COMPARED TO TYPICAL ALZHEIMER'S DISEASE **2018**, 14, P903-P903
- 73 P3-216: IS THE RELATION BETWEEN BLOOD PRESSURE AND COGNITION DEPENDENT ON AMYLOID PATHOLOGY OR PHYSICAL PERFORMANCE? RESULTS OF THE EMIF-AD 90+ STUDY **2018**, 14, P1153-P1153
- 72 IC-P-222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM **2018**, 14, P180-P181
- 71 P2-270: INCREASED CSF AMYLOID- β -38 AND 1-40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY **2018**, 14, P780-P781

- 70 P1-333: DETECTING CLINICALLY RELEVANT CHANGES IN DEMENTIA USING INSTRUMENTAL ACTIVITIES OF DAILY LIVING: A LONGITUDINAL VALIDATION STUDY WITH 3, 6, 9 AND 12 MONTHS FOLLOW-UP **2018**, 14, P420-P420
- 69 IC-P-066: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS **2018**, 14, P59-P60
- 68 P4-113: COMPARING THE COGNITIVE-FUNCTIONAL COMPOSITE WITH TRADITIONAL TESTS OF COGNITION AND FUNCTION: FINDINGS FROM THE CATCH-COG STUDY COHORT **2018**, 14, P1482-P1482
- 67 P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT **2018**, 14, P1161-P1161
- 66 P1-357: MEDIAN SURVIVAL IN MEMORY CLINIC COHORT IS SHORT, EVEN IN YOUNG-ONSET DEMENTIA **2018**, 14, P431-P431
- 65 P1-016: METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAM-VCI STUDY **2018**, 14, P270-P271
- 64 P1-259: SEX DIFFERENCES IN CEREBROSPINAL FLUID BIOMARKER CONCENTRATIONS ACROSS CLINICAL STAGES OF ALZHEIMER'S DISEASE **2018**, 14, P380-P380
- 63 O2-06-03: AMYLOID-LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE **2018**, 14, P632-P632
- 62 P2-248: CONTACTIN-2 AS A POTENTIAL BIOMARKER FOR MILD COGNITIVE IMPAIRMENT **2018**, 14, P768-P768
- 61 IC-06-05: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE **2018**, 14, P13-P13
- 60 O2-04-02: LONGITUDINAL COGNITIVE TRAJECTORIES OF PATIENTS WITH DISCORDANT CSF AND PET AMYLOID BIOMARKERS **2018**, 14, P621-P622
- 59 P1-418: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS **2018**, 14, P465-P465
- 58 P1-525: AMYLOID AGGREGATION IS ASSOCIATED WITH DECLINE ON DIGIT SPAN BACKWARD IN COGNITIVELY NORMAL ELDERLY MONOZYGOTIC TWINS **2018**, 14, P533-P533
- 57 P1-297: METABOLIC BLOOD-BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER'S DISEASE **2018**, 14, P401-P403
- 56 P2-153: DIFFERENT CORTICAL NEURONAL VULNERABILITY IN DEMENTIA WITH AND WITHOUT PREDOMINANT BEHAVIOURAL SYMPTOMS **2018**, 14, P726-P727
- 55 P3-438: PARAMETRIC IMAGING OF [18F]FLORBETAPIR: A TEST-RETEST STUDY IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER'S DISEASE **2018**, 14, P1281-P1282
- 54 P2-349: DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA **2018**, 14, P820-P821
- 53 P1-627: AMYLOID BURDEN IMPACTS EVERYDAY FUNCTIONING INDEPENDENT OF COGNITION AND AWARENESS IN SUBJECTIVE COGNITIVE DECLINE: FINDINGS FROM THE INSIGHT PRE-AD COHORT **2018**, 14, P581-P582

- 52 P2-363: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS **2018**, 14, P830-P831
- 51 F1-02-04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY **2018**, 14, P204-P204
- 50 P2-134: THE ADDED VALUE OF EXTREME PHENOTYPES IN ALZHEIMER'S DISEASE CASE-CONTROL STUDIES **2018**, 14, P719-P719
- 49 P2-360: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM **2018**, 14, P827-P829
- 48 P3-264: UNBIASED METHOD TO DETERMINE CUT-POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION **2018**, 14, P1176-P1177
- 47 O2-03-03: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY **2018**, 14, P615-P617
- 46 P4-038: IS SORL1 AN AUTOSOMAL DOMINANT ALZHEIMER GENE? **2018**, 14, P1447-P1447
- 45 O5-04-01: A RARE GENETIC VARIANT IN THE PLCG2 GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE **2018**, 14, P1648-P1649
- 44 O2-14-04: IDENTIFYING BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA AMONG PATIENTS WITH A LATE-ONSET FRONTAL LOBE SYNDROME: SUMMARY RESULTS OF THE LOF STUDY **2018**, 14, P657-P658
- 43 IC-P-093: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS **2018**, 14, P79-P80
- 42 IC-P-033: LONGITUDINAL CHANGES IN GREY MATTER CONNECTIVITY ARE RELATED TO COGNITIVE DECLINE IN PRODROMAL ALZHEIMER'S DISEASE **2018**, 14, P37-P38
- 41 P3-342: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTI-STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES **2018**, 14, P1214-P1215
- 40 IC-P-032: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTI-STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES **2018**, 14, P36-P37
- 39 P3-272: A COMPARISON OF EEG CONNECTIVITY OUTCOME MEASURES FOR ALZHEIMER'S DISEASE IN A DOUBLE-BLINDED RANDOMIZED CLINICAL TRIAL OF PQ912 **2018**, 14, P1181-P1182
- 38 P3-277: IMPAIRMENT IN COMPLEX ACTIVITIES OF DAILY LIVING IS RELATED TO NEURODEGENERATION IN ALZHEIMER'S DISEASE SPECIFIC REGIONS **2018**, 14, P1183-P1184
- 37 P3-445: FACTORS PREDICTING MORTALITY AT THE MEMORY CLINIC AT SIRIRAJ HOSPITAL: 815 THAI COHORT **2018**, 14, P1286-P1286
- 36 P1-291: BINDING PROPERTIES OF CURCUMIN IN POSTMORTEM BRAIN TISSUE: TOWARD AMYLOID IMAGING IN THE RETINA? **2018**, 14, P397-P398
- 35 IC-P-110: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE **2018**, 14, P94-P95

- 34 F5-05-04: THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE **2018**, 14, P1633-P1633
- 33 P1-467: DISEASE-STAGE-SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE **2018**, 14, P500-P501
- 32 O3-13-06: TAKING AMYLOID PET INTO THE CLINIC: INDIVIDUALIZED RISK PREDICTION IN MCI PATIENTS THE ABIDE PROJECT **2018**, 14, P1058-P1058
- 31 O2-09-05: EXTENSION AND VALIDATION OF AN AMYLOID STAGING MODEL: ASSOCIATIONS WITH CLINICAL MEASURES **2018**, 14, P643-P643
- 30 O2-15-04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS **2018**, 14, P661-P662
- 29 O5-01-03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NON-NEGATIVE MATRIX FACTORIZATION **2018**, 14, P1638-P1639
- 28 IC-P-005: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [18F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMI-QUANTITATIVE AND QUANTITATIVE METHODS **2018**, 14, P16-P17
- 27 P2-284: NUTRITIONAL MARKERS ASSOCIATED WITH CLINICAL PROGRESSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD STUDY **2018**, 14, P789-P790
- 26 FTS3-01-02: EUROPEAN PERSPECTIVE ON CLINICAL AMYLOID IMAGING **2018**, 14, P1004-P1004
- 25 P3-617: NUTRITIONAL INTAKE IN SUBJECTIVE COGNITIVE DECLINE: ROOM FOR IMPROVEMENT? **2018**, 14, P1366-P1367
- 24 P3-568: PROGNOSIS OF INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT REVERTING TO NORMAL COGNITION **2018**, 14, P1341-P1342
- 23 F4-08-01: PLASMA AMYLOID AS A PRE-SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE **2018**, 14, P1394-P1394
- 22 F1-02-02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION **2018**, 14, P201-P202
- 21 P2-251: NEUROPATHOLOGICAL HALLMARKS OF ALZHEIMER'S DISEASE IN POSTMORTEM AD RETINAS **2018**, 14, P770-P771
- 20 O1-10-05: ELECTRO-ENCEPHALOGRAPHY AS A PRODROMAL MARKER OF DEMENTIA WITH LEWY BODIES **2018**, 14, P245-P245
- 19 P3-355: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [18F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMI-QUANTITATIVE AND QUANTITATIVE METHODS **2018**, 14, P1221-P1222
- 18 F1-02-01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT-LIGHT AND YKL-40 TO A β APOE ϵ AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY **2018**, 14, P201-P201
- 17 P2-458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY **2018**, 14, P895-P896

16	F1-02-03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY 2018 , 14, P202-P204	
15	IC-P-187: CORTICAL T1-W/T2-W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS 2018 , 14, P156-P156	
14	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022 , 3, 100128	0
13	CSF proteomic signature predicts progression to Alzheimer's disease dementia.. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , 2022 , 8, e12240	6
12	The Importance of Phase 2 in Drug Development for Alzheimer's Disease 2022 , 150-161	
11	Giving meaning to the scores of the Amsterdam instrumental activities of daily living questionnaire: a qualitative study.. <i>Health and Quality of Life Outcomes</i> , 2022 , 20, 47	3
10	Psychosocial effects of Corona virus measures on (pre-)dementia patients during 2 lockdown.. <i>Alzheimeris and Dementia</i> , 2021 , 17 Suppl 7, e053995	1.2
9	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy 2020 , 15, e0226784	
8	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy 2020 , 15, e0226784	
7	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy 2020 , 15, e0226784	
6	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy 2020 , 15, e0226784	
5	EEG slowing in predementia Alzheimer's disease is compatible with neuronal hyperactivity: A multiscale computational modeling study.. <i>Alzheimeris and Dementia</i> , 2021 , 17 Suppl 3, e053535	1.2
4	Neuropathological hallmarks of Alzheimer's disease in centenarians, in the context of aging.. <i>Alzheimeris and Dementia</i> , 2021 , 17 Suppl 3, e053600	1.2
3	Neuroproteomics of cognitively healthy centenarians in the context of aging and Alzheimer's disease.. <i>Alzheimeris and Dementia</i> , 2021 , 17 Suppl 3, e053681	1.2
2	Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum.. <i>Alzheimeris and Dementia</i> , 2021 , 17 Suppl 3, e055451	1.2
1	Effects of age, amyloid, sex, and β on the CSF proteome in normal cognition.. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022 , 14, e12286	5.2